学术周报 · IF≥10 或专科旗舰刊
心血管科领域文献阅读汇编
2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| European heart journal | 8 | IF 45.3 |
| Circulation | 6 | IF 41.3 |
| Science advances | 4 | IF 13.9 |
| European journal of preventive cardiology | 4 | IF 10.0 |
| Hypertension (Dallas, Tex. : 1979) | 4 | IF 9.8 |
| Stroke | 3 | IF 11.1 |
| Circulation. Arrhythmia and electrophysiology | 2 | IF 9.3 |
| Environmental science & technology | 2 | IF 12.2 |
| European journal of heart failure | 2 | IF 10.3 |
| Nature cardiovascular research | 2 | IF 12.6 |
1高血压 (9篇)
临床研究 (5篇)
The 2025 American Heart Association/American College of Cardiology guideline adopted the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to guide antihypertensive treatment, but whether PREVENT risk groups identify patients who benefit more from intensive blood pressure (BP) control is uncertain. We evaluated intensive BP control across PREVENT risk groups in the China Rural Hypertension Control Project. We analyzed 21 872 hypertensive adults from 326 Chinese villages. Participants received intensive BP control (target <130/80 mm Hg) or usual care and were classified as low risk (<5%), borderline risk (5.0%-7.4%), intermediate risk (7.5%-19.9%), or high risk (≥20%). The primary outcome was a composite of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death). Safety, net benefit, and life expectancy were assessed. Over a median of 3.02 years, intensive BP control was associated with lower cardiovascular risk in the low-risk (hazard ratio, 0.53 [95% CI, 0.29-0.97]), intermediate-risk (hazard ratio, 0.58 [95% CI, 0.49-0.69]), and high-risk groups (hazard ratio, 0.60 [95% CI, 0.47-0.77]), but not the borderline-risk group (hazard ratio, 0.80 [95% CI, 0.51-1.26]). No significant treatment-by-risk interaction was observed. Adverse events increased mainly in intermediate- and high-risk groups. Net benefit was favorable across all groups and greatest in the high-risk group. At 45 years of age, estimated life expectancy gains were 0.94 years overall, 0.71 years in the intermediate-risk group, and 1.26 years in the high-risk group. Intensive BP control was associated with lower cardiovascular risk in 3 PREVENT risk groups, with favorable net benefit across all groups. Absolute benefit and estimated life expectancy gains were greatest among high-risk participants. PREVENT risk stratification may inform intensive BP control in community-based hypertensive populations.
中文摘要:2025年美国心脏协会/美国心脏病学会指南采用预测心血管疾病事件风险(PREVENT)方程指导降压治疗,但PREVENT风险分层是否能识别从强化血压控制中获益更多的患者尚不明确。本研究在中国农村高血压控制项目中评估了不同PREVENT风险组接受强化血压控制的效果。我们分析了来自326个中国村庄的21872名高血压成人参与者。参与者接受强化血压控制(目标<130/80 mmHg)或常规护理,并按低危(<5%)、临界风险(5.0%-7.4%)、中危(7.5%-19.9%)或高危(≥20%)进行分类。主要结局为主要心血管事件复合终点(心肌梗死、卒中、心力衰竭或心血管死亡)。研究评估了安全性、净获益和预期寿命。在中位随访3.02年的过程中,强化血压控制与低危组(风险比0.53 [95% CI, 0.29-0.97])、中危组(风险比0.58 [95% CI, 0.49-0.69])和高危组(风险比0.60 [95% CI, 0.47-0.77])的心血管风险降低相关,但临界风险组未观察到显著关联(风险比0.80 [95% CI, 0.51-1.26])。未观察到显著的治疗与风险交互作用。不良事件主要在中危和高危组增加。所有组的净获益均有利,且在高危组最大。在45岁时,估计预期寿命增益总体为0.94年,中危组为0.71年,高危组为1.26年。强化血压控制与3个PREVENT风险组的心血管风险降低相关,所有组的净获益均有利。绝对获益和估计的预期寿命增益在高危参与者中最大。PREVENT风险分层可为社区高血压人群的强化血压控制提供依据。
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.
中文摘要:代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎(MASH)在全球及韩国正带来日益增加的肝脏和心脏代谢负担。在证明司美格鲁肽对伴有纤维化的非肝硬化MASH具有组织学疗效的III期ESSENCE试验之后,临床需要针对常规诊疗的实践指导。韩国肝脏研究协会制定了关于MASH治疗中司美格鲁肽应用的专家共识声明。该15人专家小组采用RAND/UCLA适宜性方法,经过两轮评分及结构化小组讨论,对涵盖患者选择、剂量调整、疗效评估、不良事件管理及代谢合并症在内的98个临床场景进行了评级。司美格鲁肽主要适用于伴有2至3期纤维化的非肝硬化MASH患者。资格评估应采用两步策略:首先进行年龄调整的Fibrosis-4指数筛查,随后进行振动控制瞬时弹性成像(VCTE)。VCTE衍生的肝脏硬度测量值(LSM)为10至15 kPa定义为首选治疗范围;在排除肝硬化和门静脉高压的情况下,15至20 kPa也可接受;而8至10 kPa则需重复VCTE、磁共振弹性成像(适用范围为3.1至4.4 kPa)或肝活检。司美格鲁肽起始剂量为每周一次0.25 mg,每4周递增一次,目标维持剂量为2.4 mg。疗效应在至少18个月后通过无创检查进行评估;VCTE衍生的LSM降低≥30%提示治疗有效。该共识为MASH中司美格鲁肽的使用提供了结构化框架,并整合了肥胖、2型糖尿病、心血管风险及慢性肾脏病的管理。
Cardiovascular (CV) diseases and dementia share common risk factors and often coexist in older adults. Understanding the CV-brain interaction is essential for tackling their interconnected burden. This study investigated the link between CV phenotypes, brain architecture, and cognition. Overall, 15 519 UK Biobank participants without neurodegenerative diseases or stroke (median age 64 years, 49% female) were analysed. Confirmatory factor analysis aggregated 18 CV magnetic resonance imaging (MRI) biomarkers into latent variables for left ventricular systolic function (gSyst), diastolic (gDiast) function, and geometry (gGeom); arterial compliance was measured by aortic distensibility (AoD). Multivariable linear regression models evaluated associations with brain MRI phenotypes, including grey matter volume, white matter hyperintensities, MRI diffusion white matter microstructure, and hippocampal volume. Models were adjusted for age, body mass index, height, mean blood pressure, and CV risk factors. Exploratory mediation models evaluated whether hippocampal volume accounted for associations between CV phenotypes and cognition. gGeom, reflecting greater myocardial mass, wall thickness, and ventricular volumes, showed the strongest association with hippocampal volume [β = 0.082 (0.048-0.117) in females; β = 0.039 (0.006-0.071) in males] and was the only CV phenotype associated with better cognition, including higher fluid intelligence and faster reaction time. Hippocampal volume significantly accounted for the positive relationship between gGeom and cognition across sexes. In contrast, gSyst, gDiast, and AoD demonstrated weaker and less consistent associations with brain structure and were unrelated to cognition. Ventricular geometry emerged as the CV phenotype most strongly associated with brain architecture and cognition. Hippocampal volume may help explain this association, but further studies are needed to investigate causality.
中文摘要:心血管疾病与痴呆症共享共同的风险因素,且常共存于老年人群中。理解心血管与大脑之间的相互作用对于应对其相互关联的负担至关重要。本研究探讨了心血管表型、大脑结构与认知之间的联系。共分析了15519名无神经退行性疾病或中风病史的英国生物银行参与者(中位年龄64岁,女性占49%)。验证性因子分析将18项心血管磁共振成像生物标志物聚合成左心室收缩功能、舒张功能和几何结构的潜在变量;动脉顺应性通过主动脉顺应性进行测量。多变量线性回归模型评估了与大脑磁共振表型的关联,包括灰质体积、白质高信号、磁共振扩散白质微结构和海马体积。模型调整了年龄、体重指数、身高、平均血压和心血管风险因素。探索性中介模型评估了海马体积是否解释了心血管表型与认知之间的关联。反映心肌质量、室壁厚度和心室容积增加的几何结构显示出与海马体积最强的关联,并且是唯一与更好认知相关的表型,包括更高的流体智力和更快的反应时间。海马体积显著介导了不同性别中几何结构与认知之间的正相关关系。相比之下,收缩功能、舒张功能和主动脉顺应性与大脑结构的关联较弱且不一致,且与认知无关。心室几何结构成为与大脑结构和认知关联最强的心血管表型。海马体积可能有助于解释这种关联,但需要进一步研究以调查因果关系。
To identify patient characteristics associated with ocular hypertension after steroid use in children. Retrospective cohort study. Children ≤18 years of age seen at a tertiary care children's hospital between 2009 and 2025 who were prescribed any type of steroid and had a documented intraocular pressure (IOP) measurement within 1 to 60 days of steroid initiation. Children with any IOP measurement >21 mmHg recorded prior to or on the day of steroid initiation were excluded. Steroid type, route of administration, and patient characteristics, including comorbidities, were extracted from the electronic medical record. Univariable and multivariable logistic regression models were used to identify factors independently associated with ocular hypertension after steroid use. Ocular hypertension among children who underwent IOP measurement after steroid initiation, defined as IOP >21 mmHg measured within 1 to 60 days of steroid initiation. Of 5,687 children included (mean age at steroid initiation 8.8 years; 54.4% male), 1,034 (18.2%) developed ocular hypertension. The most frequently prescribed steroid was fluticasone (20.0%), and the most common route of administration was inhaled/intranasal (24.8%). In multivariable analysis, glaucoma conferred the highest odds of ocular hypertension after steroid use (adjusted odds ratio [aOR], 6.77; 95% CI, 5.21-8.79), followed by prednisone relative to dexamethasone (aOR, 3.37; 95% CI, 2.30-4.93), juvenile arthritis (aOR, 1.56; 95% CI, 1.09-2.24), and uveitis (aOR, 1.52; 95% CI, 1.16-1.99). Compared with topical administration, ocular (aOR, 3.57; 95% CI, 2.39-5.33) and intravenous (aOR, 2.63; 95% CI, 1.78-3.89) routes each independently conferred higher odds of ocular hypertension. Age, sex, race, ethnicity, diabetes, and asthma were not independently associated with ocular hypertension. Nearly 1 in 5 children with an IOP measurement within 1 to 60 days of steroid initiation developed ocular hypertension. Glaucoma, uveitis, juvenile arthritis, and non-topical routes of administration-particularly ocular and intravenous-were the strongest risk factors, highlighting the importance of ophthalmic monitoring in children receiving glucocorticoid therapy.
中文摘要:目的:识别儿童使用糖皮质激素后发生眼压升高的相关患者特征。方法:回顾性队列研究。纳入2009年至2025年间在三级儿童医院就诊且年龄小于等于18岁、处方了任何类型糖皮质激素并在激素起始后1至60天内有记录的眼内压(IOP)测量的儿童。排除在激素起始前或当天任何IOP测量值大于21 mmHg的儿童。从电子病历中提取激素类型、给药途径及患者特征(包括合并症)。采用单变量和多变量逻辑回归模型识别与激素使用后眼压升高独立相关的因素。结果:纳入5687名儿童,激素起始时平均年龄为8.8岁,男性占54.4%。其中1034名(18.2%)发生了眼压升高。最常处方的是氟替卡松(20.0%),最常见的给药途径是吸入/鼻内(24.8%)。多变量分析显示,青光眼在激素使用后导致眼压升高的几率最高(调整比值比[aOR] 6.77;95% CI 5.21-8.79),其次是泼尼松相对于地塞米松(aOR 3.37;95% CI 2.30-4.93)、幼年特发性关节炎(aOR 1.56;95% CI 1.09-2.24)和葡萄膜炎(aOR 1.52;95% CI 1.16-1.99)。与局部给药相比,眼内注射(aOR 3.57;95% CI 2.39-5.33)和静脉注射(aOR 2.63;95% CI 1.78-3.89)途径均独立增加了眼压升高的几率。年龄、性别、种族、民族、糖尿病和哮喘与眼压升高无独立关联。结论:在激素起始后1至60天内进行IOP测量的儿童中,近五分之一发生了眼压升高。青光眼、葡萄膜炎、幼年特发性关节炎以及非局部给药途径(尤其是眼内注射和静脉注射)是最强的危险因素,强调了接受糖皮质激素治疗的儿童进行眼科监测的重要性。
Antenatal inflammation drives postpartum cardiac dysfunction in hypertensive disorders of pregnancy.
Hypertensive disorders of pregnancy (HDPs), including preeclampsia and gestational hypertension, are strongly associated with maternal cardiac dysfunction during and after pregnancy. We hypothesized that maternal inflammation drives persistent postpartum cardiac maladaptation after HDPs. We conducted a prospective longitudinal study assessing cardiac function and circulating inflammatory profiles during pregnancy and 3-6 months postpartum, complemented by a preclinical mechanistic mouse model recapitulating key antenatal and postpartum immune and cardiac features of HDPs. Here we show that distinct antenatal inflammatory signatures, including elevated chemokines, correlated with adverse left ventricular structure and function 3-6 months postpartum, despite resolution of systemic inflammation. Mechanistically, our preclinical HDP mouse model demonstrates that reduced antenatal progesterone, also observed in patients with HDPs, drives inflammation and postpartum cardiac dysfunction. Antenatal (embryonic day 14.5), but not postpartum (postpartum day 28), progesterone treatment prevented postpartum cardiac dysfunction, identifying both a potential mechanistic and therapeutic strategy to reduce long-term maternal cardiovascular morbidity.
中文摘要:妊娠期高血压疾病(HDPs),包括子痫前期和妊娠高血压,与孕产妇在孕期及产后的心脏功能障碍密切相关。我们假设母体炎症驱动了 HDPs 后持续性的产后心脏适应不良。我们开展了一项前瞻性纵向研究,评估了孕期及产后 3-6 个月的心脏功能和循环炎症谱,并辅以重现 HDPs 关键产前和产后免疫及心脏特征的临床前机制小鼠模型。结果显示,尽管全身性炎症已消退,但不同的产前炎症特征(包括趋化因子升高)与产后 3-6 个月的左心室结构和功能不良相关。在机制方面,我们的临床前 HDP 小鼠模型表明,产前孕酮减少(在 HDPs 患者中也观察到)驱动了炎症和产后心脏功能障碍。产前(胚胎第 14.5 天)而非产后(产后第 28 天)的孕酮治疗可预防产后心脏功能障碍,这既是一种潜在的机制解释,也是一种降低长期母体心血管发病率的治疗策略。
基础研究 (4篇)
2025 Harriet Dustan Lecture: Sex Differences in Immune-Mediated Hypertension: Why Menopause Matters.
Hypertension is an inflammatory disease with the immune system playing a key role in mediating hypertensive outcomes and end-organ damage. The risk of hypertension is greater in men than in women before women enter menopause. After menopause, a woman's risk for developing hypertension increases and accelerates beyond that of age-matched men. Moreover, after menopause, the rate of hypertension control in women is lower than in men. Indeed, cardiovascular drug efficacy in women is different from that in men, with recent studies highlighting serious side effects of angiotensin-converting enzyme inhibitors and β-blockers in postmenopausal women. Despite these sex differences, sex-specific clinical practice guidelines are still sparse, as is the consideration of a woman's hormonal status. In addition, preclinical models of immune-mediated hypertension are still mainly performed in male animals. The goal of this review is to highlight recent advancements in the field of sex differences in immune-mediated hypertension and to identify the major gaps in understanding immune mechanisms that lead to hypertension development in males and females, and as menopause progresses.
中文摘要:高血压是一种炎症性疾病,免疫系统在介导高血压结局和终器官损伤中发挥关键作用。女性在绝经前患高血压的风险高于男性。绝经后,女性发展为高血压的风险增加并加速超过同龄男性。此外,绝经后女性的高血压控制率低于男性。事实上,心血管药物在女性中的疗效与男性不同,近期研究强调了血管紧张素转换酶抑制剂和β受体阻滞剂在绝经后女性中严重的副作用。尽管存在这些性别差异,但针对性别的临床实践指南仍然稀缺,对女性激素状态的考虑也较少。此外,免疫介导高血压的临床前模型仍主要在雄性动物中进行。本综述旨在突出免疫介导高血压性别差异领域的最新进展,并确定理解导致男性和女性高血压发展的免疫机制的主要知识空白,以及绝经进展过程中的相关问题。
Female and male kidneys exhibit markedly different patterns of transporter abundance and activity along the nephron, yet the physiological significance of the differences remains incompletely understood. Recent experimental and computational studies suggest that many of these differences can be interpreted through the lens of pressure natriuresis, the kidney's primary mechanism for long-term regulation of extracellular volume and arterial pressure. We review evidence that the female nephron exhibits a transport architecture that may facilitate enhanced pressure natriuresis and greater flexibility in effective circulating volume regulation. This framework provides new insights into sex differences in acute and chronic blood pressure control and connects pressure-natriuretic mechanisms with renal adaptations during pregnancy and lactation, hypertension, and aging.
中文摘要:男女肾脏在肾单位不同部位的转运蛋白丰度和活性表现出显著差异,但这些差异的生理意义尚未完全阐明。近期的实验与计算研究表明,许多此类差异可通过压力钠尿这一肾脏调节细胞外液量和动脉压长期平衡的主要机制来解释。我们综述了证据,表明女性肾小管具有可能促进增强型压力钠尿及有效循环血量调节灵活性的转运架构。该框架为急性与慢性血压控制中的性别差异提供了新见解,并将压力钠尿机制与妊娠、哺乳、高血压及衰老过程中的肾脏适应联系起来。
Recent evidence suggests that individuals with smaller left ventricular (LV) volumes and high LV ejection fraction face an increased risk of cardiovascular morbidity and mortality. Age-related cardiac changes may particularly predispose women to these risk conditions. LV morphometry was analysed by cardiac magnetic resonance imaging in 39 616 individuals (aged 45-85 years, 52.2% women) from the UK Biobank using an observational cross-sectional study design. Additional analyses were conducted in a mouse model of hormone withdrawal and ageing (118 mice aged 4-6 [young cohort] or 18-20 [aged cohort] months, 50% females) as well as in a 3D human microtissue (hMT) model assessing the cellular effects of sex hormones. Both women and men exhibited age-related reduction of LV volumes, with women showing a significantly stronger decline than men (indexed LV end-diastolic volume [LVEDVI]: r = -0.272, P = .037 vs men). A compensatory increase in baseline heart rate (HR) was more pronounced in women (r = 0.121, P < .001 vs men) resulting in a lesser age-related decline in cardiac indices in women than in men (r = -0.169 in women vs r = -0.211 in men, P = .045 vs men). In mice, sex differences in cardiac ageing were more pronounced than in humans, with age-related reductions in LV volumes alongside an increase in collagen I production (0.743 ± 0.364 vs 1.611 ± 0.372 arbitrary units [AU], P = .002 and 1.925 ± 0.27 vs 1.838 ± 0.329 AU, P = .0972 for young vs old in males), being significant only in females (LVEDVI: P < .001 for young vs old females). Withdrawal of sex hormones in mice eliminated age-related changes in LV volumes. Compensatory mechanisms accounting for smaller LV volumes, including an age-related increase in HR (377 ± 45 vs 438 ± 40 bpm, P = .012 for young vs old females) and cardiac sympathetic activity (0.206 ± 0.02 vs 0.148 ± 0.03% injected dose per mL, P = .008 for young vs old females), were significant only in female mice. In a 3D hMT model, both female and male sex hormones exerted anti-fibrotic and anti-apoptotic effects on cardiomyocytes and fibroblasts. A decline in female sex hormone production with age was observed in both species, while testosterone levels remained essentially unchanged over the lifespan. Age-related cardiac changes affect both women and men in similar ways, but are more pronounced in women-likely reflecting a greater decline in sex hormones. This is associated with more prominent compensatory mechanisms to offset their disadvantage of having a smaller heart. Animal and tissue models support these findings by revealing hormone- and sex-specific effects on cardiac structure and sympathetic regulation.
中文摘要:近期证据表明左心室容积较小且左心室射血分数较高的人群面临更高的心血管发病率和死亡率风险。与年龄相关的心脏变化可能使女性更易处于这些风险状态。本研究采用观察性横断面设计,通过心脏磁共振成像分析了英国生物银行中39616名个体(45-85岁,女性占52.2%)的左心室形态学特征。另在激素撤退和衰老的小鼠模型(118只小鼠,4-6个月为年轻组,18-20个月为老年组,雌性占50%)以及评估性激素细胞效应的3D人微组织模型中进行了额外分析。男女均表现出与年龄相关的左心室容积减少,但女性下降幅度显著强于男性(索引化左心室舒张末期容积LVEDVI:r=-0.272,P=.037 vs 男性)。基线心率增加这一代偿性变化在女性中更为明显(r=0.121,P<.001 vs 男性),导致女性心脏指数随年龄的下降幅度小于男性(女性r=-0.169 vs 男性r=-0.211,P=.045 vs 男性)。在小鼠中,与人类相比,心脏衰老的性别差异更为显著,表现为左心室容积随年龄减少及I型胶原生成增加(年轻vs老年雄性:0.743±0.364 vs 1.611±0.372任意单位AU,P=.002;1.925±0.27 vs 1.838±0.329 AU,P=.0972),该变化仅在雌性中显著(LVEDVI:年轻vs老年雌性P<.001)。小鼠中性激素的撤退消除了左心室容积的年龄相关变化。代偿机制包括心率增加(年轻vs老年雌性:377±45 vs 438±40 bpm,P=.012)和心脏交感神经活性增强(年轻vs老年雌性:0.206±0.02 vs 0.148±0.03%注射剂量/mL,P=.008),这些变化仅在雌性小鼠中显著。在3D人微组织模型中,雌性和雄性性激素均对心肌细胞和成纤维细胞发挥抗纤维化和抗凋亡作用。两种物种均观察到随年龄增长雌性性激素产生减少,而睾酮水平在整个生命周期中基本保持不变。与年龄相关的心脏变化以相似方式影响男女,但在女性中更为显著,这可能反映了性激素更大的下降幅度。这与更显著的代偿机制相关,旨在抵消心脏较小带来的劣势。动物和组织模型支持这些发现,揭示了激素和性别特异性对心脏结构和交感神经调节的影响。
The Evo2 Variant Effect Database (Evo2VED; https://dnallmved.org/) is a publicly accessible resource cataloging precomputed Evo2-derived variant effect scores, defined as allelic score differences, for 6.48 million human variants common in the gnomAD non-Finnish European population. Evo2VED includes scores from the 7B and 40B models under three scoring schemes, alongside annotations of variant function, evolutionary constraint, allele age, and disease associations. It integrates genome-wide association study (GWAS) data from UK Biobank, FinnGen, and the Million Veteran Program. Three complementary modules support variant-level interpretation, regional and region-set exploration, and trait-level analysis through flexible queries, interactive visualizations, and downloadable results. Evo2VED also catalogs associations between Evo2 annotations and per-SNP heritability across thousands of traits from these biobanks. A guided workflow connects GWAS with associated regions and individual variant evidence. Case studies of hypertension and depression illustrate how regional comparisons of Evo2 scores and GWAS signals can guide candidate variant prioritization. Evaluations using massively parallel reporter assays, molecular QTLs, fine-mapping probabilities, and clinical annotations assess associations with Evo2 scores alone and their added value beyond conservation and regulatory annotations. By providing accessible scores, contextual annotations, and comparative analyses, Evo2VED facilitates exploration and application of genomic language model predictions in human genetics research.
中文摘要:Evo2 Variant Effect Database(Evo2VED;https://dnallmved.org/)是一个公开可访问的资源,收录了648万个在gnomAD非芬兰欧洲人群中常见的DNA变异的预计算Evo2衍生变异效应评分,定义为等位基因评分差异。Evo2VED包含来自7B和40B模型在三种评分方案下的评分,以及变异功能、进化约束、等位基因年龄和疾病关联的注释。它整合了来自UK Biobank、FinnGen和百万退伍军人计划的基因组范围关联研究(GWAS)数据。三个互补模块支持通过灵活查询、交互式可视化和可下载结果进行变异水平解释、区域及区域集探索和性状水平分析。Evo2VED还收录了这些生物银行中数千个性状的Evo2注释与每单核苷酸多态性(SNP)遗传力之间的关联。一个引导式工作流程将GWAS与相关区域和单个变异证据联系起来。高血压和抑郁症的案例研究说明了Evo2评分的区域比较和GWAS信号如何指导候选变异的优先排序。利用大规模平行报告基因测定、分子数量性状位点、精细映射概率和临床注释进行的评估,分析了仅基于Evo2评分的关联及其在保守性和调控性注释之外的附加价值。通过提供可访问的评分、上下文注释和比较分析,Evo2VED促进了基因组语言模型预测在人类遗传学研究中的探索和应用。
2心力衰竭 (7篇)
临床研究 (7篇)
Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.
中文摘要:成人新型心力衰竭药物的随机对照试验提供了有力证据,显示其能改善生活质量、减少住院并降低死亡率,从而影响了当前的治疗指南。相比之下,支持儿童新型心力衰竭疗法临床益处的数据仍然有限。为了评估当代处方实践和临床医生观点,我们调查了美国和加拿大的儿科心力衰竭医生,了解他们在儿童中使用血管紧张素受体-脑啡肽酶抑制剂、钠-葡萄糖协同转运蛋白2抑制剂以及铁补充治疗的情况。我们还审查了现有的儿科文献,并总结了在缺乏严格证据的情况下,这些疗法报告的副作用、剂量经验和实用指导。
In low- and middle-income countries (LMICs), iron-deficient anemia is highly prevalent and may compound the cardiovascular stress of pregnancy, yet its contribution to maternal acute heart failure (AHF) is poorly understood. To investigate the association of maternal anemia and iron status with AHF in pregnancy and post partum in India. This multicenter, unmatched, prospective case-control study recruited participants from 10 hospitals across 4 Indian states from February 2019 to November 2024. Incident cases were pregnant or postpartum women with clinically diagnosed AHF. Controls were women without history or symptoms of heart disease within 48 hours post partum. Data were analyzed from March 2025 to April 2026. Maternal anemia and iron status. Blood samples collected at recruitment were analyzed for hemoglobin, ferritin, transferrin saturation, soluble transferrin receptor, and hepcidin. The outcome of interest was AHF, defined using clinical criteria. Multivariable logistic regression models assessed associations of iron status and anemia with AHF, adjusting for potential confounders, including hypertensive disorders of pregnancy. Subgroup analyses were performed in women with echocardiographic abnormalities and peripartum cardiomyopathy. The discriminatory capacity of a model including anemia present before AFH onset vs a model with established risk factors only was examined using receiver operating characteristic curves. Among 532 women with clinically diagnosed AHF (median [IQR] age, 25 [21-29] years) and 1091 controls (median [IQR] age, 25 [21-28] years), moderate and severe anemia were associated with 1.5-fold (adjusted odds ratio [aOR], 1.52; 95% CI, 1.13-2.05) and 5-fold (aOR, 5.06; 95% CI, 3.02-8.48) increased odds of AHF, respectively, compared with women without anemia. Higher soluble transferrin receptor levels (aOR, 1.44; 95% CI, 1.31-1.57) and the lowest hepcidin quintile (aOR, 2.65; 95% CI, 1.69-4.14), both indicative of iron deficiency, were independently associated with AHF. These associations persisted after adjusting for hypertensive disorders of pregnancy and after excluding women with preexisting cardiac conditions, and they were consistent in subgroups with echocardiographic abnormalities and peripartum cardiomyopathy. Adding anemia to established risk factors improved model discrimination for identifying AHF risk, increasing the AUC from 78% (95% CI, 76%-81%) to 83% (95% CI, 80%-85%) (P < .001). This case-control study found that maternal anemia and iron deficiency were independently associated with AHF during pregnancy and post partum. Further studies are needed to determine whether preventing or treating iron deficiency and anemia can reduce AHF risk and improve maternal outcomes.
中文摘要:在低收入和中等收入国家,缺铁性贫血高发且可能加剧妊娠心血管应激,但其对孕产妇急性心力衰竭的贡献尚不明确。本研究旨在探讨印度孕妇及产后妇女贫血与铁状态同妊娠期及产后急性心力衰竭的关联。这是一项多中心、非匹配的前瞻性病例对照研究,于2019年2月至2024年11月从印度4个邦的10家医院招募参与者。病例组为临床确诊患有急性心力衰竭的孕妇或产后妇女;对照组为产后48小时内无心病史或症状的妇女。数据分析时间为2025年3月至2026年4月。主要结局指标为急性心力衰竭,采用临床标准定义。收集入组时的血液样本检测血红蛋白、铁蛋白、转铁蛋白饱和度、可溶性转铁蛋白受体及肝素水平。采用多变量逻辑回归模型评估铁状态和贫血与急性心力衰竭的关联,并调整包括妊娠高血压疾病在内的潜在混杂因素。对伴有超声心动图异常及围产期心肌病的亚组进行亚组分析。通过受试者工作特征曲线检验包含发病前贫血状态的模型与仅含已知风险因素的模型在区分能力上的差异。在532名临床确诊急性心力衰竭妇女(中位年龄25岁,四分位距21-29岁)和1091名对照妇女(中位年龄25岁,四分位距21-28岁)中,与无贫血妇女相比,中度及重度贫血患者发生急性心力衰竭的风险分别增加1.5倍(调整比值比1.52;95%置信区间1.13-2.05)和5倍(调整比值比5.06;95%置信区间3.02-8.48)。可溶性转铁蛋白受体水平升高(调整比值比1.44;95%置信区间1.31-1.57)及肝素最低五分位数(调整比值比2.65;95%置信区间1.69-4.14),两者均提示缺铁,与急性心力衰竭独立相关。在调整妊娠高血压疾病并排除既往存在心脏病的妇女后,这些关联依然存在,且在超声心动图异常及围产期心肌病亚组中结果一致。将贫血纳入已知风险因素提高了模型识别急性心力衰竭风险的区分度,AUC从78%(95%置信区间76%-81%)提升至83%(95%置信区间80%-85%)(P<.001)。该病例对照研究发现,孕产妇贫血及缺铁与妊娠期及产后急性心力衰竭独立相关。需进一步研究以确定预防或治疗缺铁及贫血是否能降低急性心力衰竭风险并改善孕产妇结局。
Despite substantial declines over the past decade, China's PM2.5 levels remain far above current WHO guidelines. PM2.5 is a recognized non-negligible risk factor for heart failure (HF), as a mixture, but the specific chemical constituents driving risks across HF subtypes remain unclear. Considering the significant heterogeneity in the etiology and pathophysiology among different HF subtypes, we explored the relationship between chemical constituents of PM2.5 and these HF subtypes. Additionally, we identified the most critical toxic constituent in the Kailuan prospective cohort of 101,521 Chinese adults followed from 2006 to 2021. Over a 14.83-year median follow-up, all chemical constituents of PM2.5 were associated with elevated risk across various HF subtypes, with notably stronger effects on early onset compared to late-onset HF. Moreover, black carbon (BC) (40.2%-48.7%) was the main contributor to overall HF, late-onset HF, and HF with reduced ejection fraction (HFrEF) and mildly reduced (HFmrEF), whereas NH4+ (28.2%) and BC (28.1%) primarily drove early onset HF, and OM (34.8%) was the key constituent for HFpEF. Chronic exposure to specific-constituents of PM2.5 increases various HF subtypes risk, underscoring the importance for regional and constituent-specific regulations to alleviate HF burden.
中文摘要:尽管过去十年中国PM2.5水平大幅下降,但仍远高于当前WHO指南标准。PM2.5作为一种混合物是公认的心力衰竭(HF)不可忽视的风险因素,但驱动不同HF亚型风险的具体化学成分尚不明确。考虑到不同HF亚型在病因学和病理生理学上的显著异质性,我们探讨了PM2.5化学成分与这些HF亚型之间的关系。此外,我们在2006年至2021年随访的101,521名中国成年人的开滦前瞻性队列中确定了最关键的毒性成分。在中位随访14.83年的过程中,PM2.5的所有化学成分均与各种HF亚型的风险升高相关,且对早发性HF的影响显著强于晚发性HF。此外,黑碳(BC)(40.2%-48.7%)是整体HF、晚发性HF以及射血分数降低的心力衰竭(HFrEF)和轻度降低的心力衰竭(HFmrEF)的主要贡献者,而NH4+(28.2%)和BC(28.1%)主要驱动早发性HF,OM(34.8%)则是射血分数保留的心力衰竭(HFpEF)的关键成分。慢性暴露于PM2.5的特定成分会增加各种HF亚型的风险,强调了制定区域性和成分特异性法规以减轻HF负担的重要性。
The role of guideline-directed medical therapy (GDMT) in patients with cardiogenic shock (CS) supported by mechanical circulatory support remains poorly defined. The feasibility and potential benefits of early GDMT initiation during Impella support are uncertain. We analyzed a multicenter prospective registry of consecutive patients with CS treated with Impella between 2020 and 2024. GDMT exposure was defined as the number of heart failure therapies administered at device explantation. The primary outcome was in-hospital mortality. Multivariable logistic regression adjusted for clinical severity and early shock trajectory. Landmark analysis excluded patients dying within 5 days, while mixed-effects models accounted for center-level clustering. Among 140 patients (mean age 61 years; 20% female), 40% received concomitant ECMO (ECPella). In-hospital mortality was 38%. At explantation, 43% received at least one GDMT agent. Greater GDMT exposure was independently associated with lower mortality (OR 0.28 per additional therapy; 95% CI 0.14-0.58; p<0.001). This association remained consistent in landmark analysis (adjusted OR 0.31; 95% CI 0.16-0.66; p<0.001) and after excluding patients with cardiac arrest (adjusted OR 0.48; 95% CI 0.23-0.88; p=0.002). A graded relationship between GDMT intensity and survival was observed. Center-level variability was negligible (intraclass correlation coefficient 0.02). In patients with CS supported by Impella, early GDMT implementation was feasible in a substantial proportion of patients. Greater GDMT exposure at device explantation was associated with lower in-hospital mortality. Ventricular unloading may provide an opportunity to initiate outcome-modifying therapies during the acute phase of CS.
中文摘要:机械循环支持下心源性休克患者接受指南指导的药物治疗的作用尚不明确,早期启动该疗法的可行性及潜在益处仍不确定。本研究分析了2020年至2024年间使用Impella治疗心源性休克患者的多中心前瞻性登记数据。指南指导药物治疗暴露量定义为拔除设备时给予的心衰治疗数量。主要结局为院内死亡率。采用多变量逻辑回归调整临床严重程度和早期休克轨迹,地标分析排除了5天内死亡的患者,混合效应模型则考虑了中心水平的聚类效应。在140名患者(平均年龄61岁;女性占20%)中,40%接受了ECMO联合治疗。院内死亡率为38%。拔除设备时,43%的患者至少接受了一种指南指导药物治疗。更高的指南指导药物治疗暴露量与较低的死亡率独立相关(每增加一种治疗OR为0.28;95%CI 0.14-0.58;p<0.001)。地标分析中这一关联保持一致(调整OR 0.31;95%CI 0.16-0.66;p<0.001),排除心脏骤停患者后亦然(调整OR 0.48;95%CI 0.23-0.88;p=0.002)。观察到指南指导药物治疗强度与生存率之间存在剂量反应关系。中心水平的变异性可忽略不计(组内相关系数0.02)。在使用Impella支持的心源性休克患者中,早期实施指南指导药物治疗在相当比例的患者中是可行的。拔除设备时更高的指南指导药物治疗暴露量与较低的院内死亡率相关。心室卸载可能为在心源性休克急性期启动改善预后的治疗提供了机会。
Elderly patients constitute a growing proportion of patients with heart failure with reduced ejection fraction (HFrEF), yet remain underrepresented in randomized clinical trials. We evaluated the impact of age on the implementation of guideline-directed medical therapy (GDMT) in HFrEF. TITRATE-HF is a prospective, multicentre registry (enrolment June 2022-February 2024) including patients with de novo, chronic, and worsening heart failure (HF). For the current analysis, HFrEF patients were categorized by age (<65, 65-74, and ≥75 years). We assessed GDMT implementation, tolerability, and clinical outcomes (composite endpoint: first HF hospitalization or all-cause death). The cohort included 980 patients aged <65 years (29%), 1120 patients aged 65-74 years (33%), and 1267 patients aged ≥75 years (38%). At 12-month follow-up, younger patients more frequently received GDMT, with quadruple therapy prescribed in 68% of those aged <65 years, 61% aged 65-74 years, and 51% aged ≥75 years (P < .001). In de novo HFrEF, age-related differences were observed within weeks after diagnosis, with faster and more extensive GDMT intensification in younger patients. Still, rates of treatment downgrades and the distribution of side effects were largely similar across age groups. Significant left ventricular ejection fraction (LVEF) improvement was observed in all age groups (all P < .001). The use of quadruple therapy at 6 months was associated with a lower risk of the composite endpoint between 6 and 12 months (adjusted hazard ratio 0.65, 95% confidence interval 0.50-0.86, P = .002), with consistent associations across age groups (P for interaction = .46). Elderly patients with HFrEF received less intensive GDMT. Age-related differences emerged early after diagnosis, with fewer treatment intensifications in elderly patients but largely similar downgrade rates across age groups. These findings highlight the need for improved implementation strategies to optimize guideline-directed therapy and dosing levels in the ageing HFrEF population.
中文摘要:老年患者占射血分数降低的心力衰竭(HFrEF)患者的比例日益增加,但在随机临床试验中代表性不足。本研究评估了年龄对HFrEF患者指南指导的药物治疗(GDMT)实施的影响。TITRATE-HF是一项前瞻性多中心登记研究(入组时间为2022年6月至2024年2月),纳入新发、慢性及加重的心力衰竭患者。本次分析中,HFrEF患者按年龄分为三组:小于65岁、65至74岁以及75岁及以上。我们评估了GDMT的实施情况、耐受性及临床结局(复合终点为首次心力衰竭住院或全因死亡)。队列包括980名小于65岁的患者(29%)、1120名65至74岁的患者(33%)和1267名75岁及以上的患者(38%)。在12个月随访时,年轻患者更常接受GDMT治疗,其中小于65岁患者中四联疗法处方率为68%,65至74岁为61%,75岁及以上为51%(P < .001)。在新发HFrEF中,诊断后数周内即观察到年龄相关的差异,年轻患者的GDMT强化更快且更广泛。尽管如此,治疗降级率和副作用分布在各年龄组间大致相似。所有年龄组均观察到显著的心室射血分数(LVEF)改善(均P < .001)。在6个月时使用四联疗法与6至12个月期间复合终点风险降低相关(调整后的风险比为0.65,95%置信区间为0.50-0.86,P = .002),且在各年龄组间关联一致(交互作用P = .46)。HFrEF老年患者接受的GDMT强度较低。诊断后早期即出现年龄相关的差异,老年患者的治疗强化较少,但各年龄组的治疗降级率大致相似。这些发现强调了需要改进实施策略,以优化老龄化HFrEF人群的指南指导治疗和剂量水平。
Cardiac magnetic resonance (CMR) plays an established role in the assessment of cardiac patients. In this document, the aim is to demonstrate and clarify the role of CMR in the clinical management of heart disease for general cardiologists in everyday clinical practice. This document will cover the clinical indications, prognostic values, and limitations of CMR in the diagnosis and follow-up of heart disease, including ischaemic heart disease, heart failure, cardiomyopathies, valvular heart disease, aortopathies, cardiac masses, pericardial conditions, and adult congenital heart disease. This document also provides a basic understanding of the use of different CMR sequences and how cardiac function is assessed. With the increasing number of patients with cardiac implantable electronic devices, a brief understanding and advice on the use of CMR in this growing patient population who may need a scan during their lifetime is discussed. This document outlines the clinical applications of CMR and its use in everyday clinical practice for cardiologists who are not experts in CMR.
中文摘要:心脏磁共振成像在心脏患者评估中已确立其重要地位。本文旨在向普通心内科医生阐明心脏磁共振成像在日常临床实践中对心脏病临床管理的作用。内容涵盖心脏磁共振成像在心脏病诊断与随访中的临床适应症、预后价值及局限性,包括缺血性心脏病、心力衰竭、心肌病、瓣膜性心脏病、主动脉疾病、心脏肿瘤、心包疾病及成人先天性心脏病。本文还提供对不同心脏磁共振序列的使用方法及心脏功能评估的基础知识。随着植入式心脏电子装置患者数量的增加,文章讨论了针对这一可能在一生中需要进行扫描的日益增长的患者群体使用心脏磁共振成像的理解与建议。本文概述了心脏磁共振成像的临床应用及其在非心脏磁共振专家的心内科医生日常实践中的使用。
Nighttime light exposure has emerged as a potential risk factor for cardiovascular disease (CVD). However, its impact on cardiac structure and function remains unknown. This population-based cohort study included 11 071 UK Biobank participants who wore a wrist-worn accelerometer with an integrated light sensor for 7 days between 2013 and 2015 (baseline) and had subsequent cardiovascular magnetic resonance (CMR) imaging 3 years later. Nighttime light exposure >3 lux was estimated, and its dose-response relationships with CMR phenotypes were examined using generalized linear regression models. Associations of nighttime light exposure with incident CVD outcomes and mortality were examined using Cox models (n = 73 286). After multivariable adjustment, high (vs none) nighttime light exposure >3 lux was associated with left ventricular (LV) concentric hypertrophy and subclinical functional decline, including 2.4% (95% confidence interval 1.6%, 3.1%) greater LV mass indexed to height1.7, 1.5% (1.0%, 2.0%) greater mean wall thickness, and 1.9% (1.1%, 2.7%) lower myocardial contraction fraction. Nighttime light exposure was also associated with impaired myocardial deformation, including lower absolute global LV circumferential [-2.7% (-3.7%, -1.7%)], radial [-2.9% (-3.9%, -1.8%)], and longitudinal strain [-2.8% (-3.9%, -1.7%)] indices. Adverse associations were also observed for the right ventricle, including 0.9% (0.1%, 1.8%) greater end-diastolic and 1.6% (0.5%, 2.8%) greater end-systolic volumes indexed, and for the left atrium, including 2.3% (0.7%, 3.9%) greater maximum volume indexed and 1.1% (0.3%, 1.9%) lower ejection fraction. All associations exhibited linear dose-response relationships, with most partly mediated by shorter sleep duration (proportion mediated: 24%-49%). During 8-10 years of follow-up, participants with high (vs none) nighttime light exposure had 29% (12%, 49%) higher risk of heart failure, 15% (4%, 27%) higher risk of atrial fibrillation, 24% (7%, 44%) higher risk of myocardial infarction, 33% (11%, 59%) higher risk of stroke, and 26% (5%, 52%) higher risk of CVD mortality. Greater nighttime light exposure was associated with adverse cardiac remodelling and subclinical functional decline across multiple chambers, statistically mediated by shorter sleep duration. These findings provide potential mechanistic insights into how nighttime light exposure may elevate CVD risk and highlight dark nights and adequate sleep for cardiovascular health.
中文摘要:夜间光照已成为心血管疾病的潜在危险因素,但其对心脏结构和功能的影响尚不明确。这项基于人群的队列研究纳入了11071名英国生物样本库参与者,他们在2013至2015年间佩戴带有集成光传感器的腕式加速度计7天作为基线,并在3年后接受了心血管磁共振成像检查。研究估算了夜间光照大于3勒克斯的情况,并使用广义线性回归模型分析了其与心血管磁共振表型的剂量反应关系。使用Cox模型分析了夜间光照与心血管疾病发病结局及死亡率的关系(n=73286)。多变量调整后,高(相较于无)夜间光照大于3勒克斯与左心室向心性肥厚和亚临床功能下降相关,包括左心室质量指数增加2.4%(95%置信区间1.6%至3.1%),平均壁厚度增加1.5%(1.0%至2.0%),心肌收缩分数降低1.9%(1.1%至2.7%)。夜间光照还与心肌变形受损相关,包括左心室绝对整体圆周应变、径向应变和纵向应变指数分别降低。右心室也观察到不良关联,包括舒张末期容积和收缩末期容积指数增加,左心房最大容积指数增加且射血分数降低。所有关联均呈现线性剂量反应关系,大部分部分由较短的睡眠时间介导(介导比例24%至49%)。在8至10年的随访期间,高夜间光照参与者患心力衰竭、心房颤动、心肌梗死、卒中和心血管疾病死亡的风险分别高出29%、15%、24%、33%和26%。较大的夜间光照暴露与多个心腔的不良心脏重构和亚临床功能下降相关,统计学上由较短的睡眠时间介导。这些发现为夜间光照如何增加心血管疾病风险提供了潜在的机制见解,并强调了黑暗夜晚和充足睡眠对心血管健康的重要性。
3脑卒中/脑血管病 (6篇)
临床研究 (2篇)
Depression, anxiety, and fatigue are common and disabling long-term sequelae of stroke. Whether habitual physical activity before stroke and engagement in physical activity during recovery are associated with poststroke psychological outcomes remains incompletely understood. We investigated associations between physical activity patterns and psychological outcomes during the first year after ischemic stroke. In this prospective cohort study, consecutive patients with ischemic stroke enrolled in the STROKE-CARD Registry were assessed for depression, anxiety, and fatigue at either 3- or 12-month follow-up after stroke using the Hospital Anxiety and Depression Scale and Fatigue Severity Scale. Physical activity was assessed before and after stroke with the Baecke Questionnaire. Associations between physical activity and psychological outcomes were assessed using multivariable logistic regression adjusted for age, sex, body mass index, prestroke and poststroke disability, stroke severity and localization, thrombolysis, prestroke depression, and cognitive impairment. Within 1050 patients (median age, 70 years; 35% female), 35.3% were screened positive for depression, 29.9% for anxiety, and 53.2% for fatigue at either 3 or 12 months after stroke. Both prestroke and poststroke physical activity were associated with lower odds of depression (adjusted odds ratio, 0.47 [95% CI, 0.36-0.62] and 0.45 [95% CI, 0.34-0.59]; P<0.001) and fatigue (adjusted odds ratio, 0.49 [95% CI, 0.38-0.64] and 0.49 [95% CI, 0.38-0.64]; P<0.001), and with lower odds of anxiety (adjusted odds ratio, 0.75 [95% CI, 0.57-1.00]; P=0.050) and (adjusted odds ratio, 0.71 [95% CI, 0.53-0.94]; P=0.016). High-intensity and high-volume activities were associated with the lowest prevalence of depression and fatigue (depression, 24.5%-25.7%; fatigue, 40.8%-44.1%). Endurance sports were associated with lower rates of depression (22.2%; P<0.001) and fatigue (40.6%; P<0.001), whereas strength training was associated with lower anxiety (12.8%; P=0.003). Physical activity before and after stroke was associated with lower odds of depression, anxiety, and fatigue. These findings identify physical activity as a potentially modifiable behavioral factor associated with psychological well-being after stroke and support further evaluation in intervention studies.
中文摘要:抑郁、焦虑和疲劳是卒中常见且致残的长期后遗症。卒中前习惯性体力活动及恢复期参与体力活动是否与卒中后心理结局相关尚不完全明确。本研究调查了缺血性卒中后第一年内体力活动模式与心理结局之间的关联。在这项前瞻性队列研究中,纳入STROKE-CARD登记数据库的连续缺血性卒中患者,在卒中后3个月或12个月随访时使用医院焦虑抑郁量表和疲劳严重程度量表评估抑郁、焦虑和疲劳。使用Baecke问卷评估卒中前和卒中后的体力活动。采用多变量逻辑回归分析体力活动与心理结局之间的关联,调整因素包括年龄、性别、体重指数、卒中前后残疾程度、卒中严重程度及部位、溶栓治疗、卒中前抑郁和认知障碍。在1050名患者中(中位年龄70岁,女性占35%),卒中后3个月或12个月时有35.3%的患者筛查出抑郁阳性,29.9%为焦虑阳性,53.2%为疲劳阳性。卒中前和卒中后的体力活动均与较低的抑郁风险相关(调整比值比分别为0.47 [95% CI, 0.36-0.62] 和 0.45 [95% CI, 0.34-0.59];P<0.001)和较低的疲劳风险(调整比值比均为0.49 [95% CI, 0.38-0.64] 和 0.49 [95% CI, 0.38-0.64];P<0.001),以及与较低的焦虑风险相关(调整比值比分别为0.75 [95% CI, 0.57-1.00];P=0.050 和 0.71 [95% CI, 0.53-0.94];P=0.016)。高强度和高容量的活动与最低的抑郁和疲劳患病率相关(抑郁24.5%-25.7%;疲劳40.8%-44.1%)。耐力运动与较低的抑郁发生率(22.2%;P<0.001)和疲劳发生率(40.6%;P<0.001)相关,而力量训练与较低的焦虑发生率(12.8%;P=0.003)相关。卒中前和卒中后的体力活动均与较低的抑郁、焦虑和疲劳风险相关。这些发现表明体力活动是与卒中后心理福祉相关的潜在可改变行为因素,并支持在干预研究中进一步评估。
Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis.
Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.
中文摘要:与常规治疗相比,Andexanet可减少急性Xa因子抑制剂相关脑出血患者的血肿扩大,但伴随血栓事件风险。本研究汇总接受Andexanet治疗的试验参与者数据,以确定血栓事件的基线预测因素。对ANNEXA-I和ANNEXA-4试验中接受Andexanet治疗的成人参与者进行二次分析,这些参与者患有急性危及生命的Xa因子抑制剂相关出血。采用分层Cox比例风险模型考察基线变量与动脉或所有血栓事件及死亡率的关联。使用以动脉事件为时间依赖性协变量的分层Cox回归模型,在调整临床协变量后考察动脉事件与死亡率的关联。741名参与者(平均年龄78.5岁,男性占54.5%)中,593人(80.0%)患有颅内出血,109人(14.7%)患有胃肠道出血。77名(10.4%)参与者发生≥1次血栓事件,147名(19.8%)死亡。随机分组后动脉和静脉血栓栓塞事件的中位发生时间分别为3.5天(四分位距2.0-12.0)和14.0天(四分位距10.0-20.0)。未发现基线因素与所有血栓事件相关。动脉血栓事件与既往心肌梗死(风险比2.64,95%置信区间1.33-5.26)、高剂量资格(风险比2.44,95%置信区间1.33-4.48)、女性性别(风险比1.78,95%置信区间1.00-3.16)和年龄(每年风险比1.04,95%置信区间1.00-1.08)相关。死亡率与动脉血栓事件(风险比2.68,95%置信区间1.64-4.36)、既往充血性心力衰竭(风险比2.53,95%置信区间1.76-3.63)、脑出血或脑室内出血(风险比1.90,95%置信区间1.20-3.01)和年龄(每年风险比1.06,95%置信区间1.03-1.08)相关。随机分组后启动抗凝治疗与血栓事件减少相关。在Andexanet治疗的Xa因子抑制剂相关出血中,基线因素与动脉血栓事件相关,可用于指导治疗决策。启动抗凝治疗可减少血栓事件的发生。
基础研究 (4篇)
Recent evidence has suggested that dysfunction of the autophagy-lysosome system was a crucial factor leading to neuronal damage, yet the underlying regulatory mechanisms remain unclear. Studies have reported that Toll like receptor 9 (TLR9) is required for autophagic flux. In our investigation, we observed that TLR9 was significantly upregulated and exerted a protective role through promoting the fusion of autophagosomes and lysosomes in the stroke models. Mechanistically, we found that tripartite motif-containing protein 31 (TRIM31) interacted with TLR9 and promoted the k48-linked polyubiquitination of TLR9, consequently facilitated its degradation in a proteasome-dependent pathway. Furthermore, TRIM31 led to impaired autophagosome-lysosome fusion in cerebral ischemic injury by negatively regulating TLR9. In conclusion, we identified TRIM31 as a novel E3 ubiquitin ligase for TLR9 degradation and provided a new therapeutic strategy to alleviate ischemic brain injury by enhancing autophagosome-lysosome fusion via TLR9.
中文摘要:近期证据表明自噬溶酶体系统功能障碍是导致神经元损伤的关键因素,但其潜在调控机制尚不明确。已有研究报道Toll样受体9(TLR9)是自噬通量所必需的。在本研究中,我们观察到在卒中模型中TLR9显著上调并通过促进自噬体与溶酶体融合发挥保护作用。机制上我们发现TRIM31与TLR9相互作用并促进其K48连接的多聚泛素化,从而通过蛋白酶体依赖性途径促进其降解。此外,TRIM31通过负向调控TLR9导致脑缺血损伤中自噬体与溶酶体融合受损。总之,我们确定TRIM31是TLR9降解的新型E3泛素连接酶,并通过增强自噬体与溶酶体融合提供减轻缺血性脑损伤的新治疗策略。
Hemorrhagic transformation (HT) remains a life-threatening complication after acute ischemic stroke (AIS), yet no active predictive tool is available for early risk assessment. Herein, we develop an integrated triplex electrochemical aptasensing platform for the parallel and simultaneous quantification of three HT-associated biomarkers-matrix metalloproteinase-9 (MMP-9), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1). The system enables parallel detection by inserting three independent screen-printed carbon electrodes (SPCEs) into a multi-channel electrochemical workstation, each functionalized with a distinct aptamer, allowing simultaneous quantification of MMP-9, FN, and PAI-1 within 30 min. Each SPCE is modified with a conductive polypyrrole/poly(3,4-ethylenedioxythiophene):polystyrene sulfonate/polyvinyl alcohol hydrogel and gold nanoparticles, followed by immobilization of specific thiolated aptamers via Au-S bonds. Upon target binding, aptamer conformational changes induce a concentration-dependent decrease in differential pulse voltammetry current. The sensor achieves ultralow detection limits of 4.04 fg/mL, 0.30 fg/mL, and 2.79 fg/mL for MMP-9, FN, and PAI-1, respectively, with a total assay time of 30 min. Clinical validation using plasma from 12 AIS patients demonstrates excellent agreement with enzyme-linked immunosorbent assay (mean bias <10%) and high reproducibility (RSD <5%). This work presents the first electrochemical aptasensor for FN and PAI-1 detection and provides a clinically validated, point-of-care-compatible platform for personalized HT risk prediction in thrombolytic therapy.
中文摘要:出血性转化(HT)是急性缺血性卒中(AIS)后一种危及生命的并发症,但目前尚缺乏用于早期风险评估的主动预测工具。本研究开发了一种集成三重复电化学适配体传感平台,用于平行同时定量三种与HT相关的生物标志物:基质金属蛋白酶-9(MMP-9)、纤维连接蛋白(FN)和纤溶酶原激活物抑制剂-1(PAI-1)。该系统通过将三个独立的丝网印刷碳电极(SPCEs)插入多通道电化学工作站实现并行检测,每个电极均修饰有独特的适配体,从而在30分钟内同时定量MMP-9、FN和PAI-1。每个SPCE均涂覆导电聚吡咯/聚(3,4-乙撑二氧噻吩):聚苯乙烯磺酸盐/聚乙烯醇水凝胶及金纳米颗粒,并通过Au-S键固定特异性巯基化适配体。靶标结合后,适配体构象变化导致差分脉冲伏安法电流呈浓度依赖性降低。该传感器对MMP-9、FN和PAI-1的检测限分别低至4.04 fg/mL、0.30 fg/mL和2.79 fg/mL,总检测时间为30分钟。利用12名AIS患者的血浆进行临床验证,结果显示与酶联免疫吸附测定法(ELISA)具有极好的一致性(平均偏差<10%)和高重现性(RSD <5%)。本研究首次提出了用于FN和PAI-1检测的电化学适配体传感器,并提供了一个经临床验证、适用于床旁检测的平台,用于溶栓治疗中个性化的HT风险预测。
Rehabilitation is an effective and reliable approach for promoting motor recovery after stroke. However, its efficacy decreases during the transition from the subacute to the chronic phase after stroke, posing a major barrier to complete functional recovery. This limited efficacy during the chronic phase is believed to result from declining neural plasticity. However, the molecular and cellular mechanisms regulating neural plasticity and its temporal changes after stroke remain unclear. To address this gap, we established a focal ischemic stroke mouse model that allows causal interrogation of the mechanisms responsible for the reduced efficacy of rehabilitation in the chronic phase. Using this model, we identified Lynx1, an endogenous negative allosteric modulator of nicotinic acetylcholine receptors, as a negative regulator of post-stroke neural plasticity. Lynx1 expression in layer 5 pyramidal neurons was transiently down-regulated and returned to normal levels in the peri-infarct area. Longitudinal intravital imaging revealed that Lynx1 suppression promoted synaptic clustering with increased dendritic spine turnover in the peri-infarct area, an emerging structural basis for memory formation. As anticipated, Lynx1 suppression improved spontaneous motor recovery and the efficacy of rehabilitation in the chronic phase after stroke. Furthermore, we developed a Lynx1-targeting antisense oligonucleotide and found that its administration during the chronic phase after stroke enhanced the efficacy of rehabilitation. These findings suggest that dendritic spine dynamics in the peri-infarct area are a key determinant of rehabilitation responsiveness through the regulation of clustered spine formation and that Lynx1 may represent a promising therapeutic target for augmenting dendritic plasticity after stroke.
中文摘要:康复是促进卒中后运动功能恢复的有效可靠方法。然而,其疗效在卒中后从亚急性期向慢性期过渡时下降,构成了完全功能恢复的主要障碍。这种慢性期疗效受限被认为源于神经可塑性下降。然而,调节神经可塑性及其卒中后时间变化的分子和细胞机制仍不清楚。为填补这一空白,我们建立了局灶性缺血性卒中小鼠模型,以因果性地探究导致慢性期康复疗效降低的机制。利用该模型,我们发现Lynx1(烟碱型乙酰胆碱受体的内源性负变构调节剂)是卒中后神经可塑性的负调控因子。Lynx1在第五层锥体神经元中的表达短暂下调,并在梗死周围区域恢复正常水平。纵向活体成像显示,抑制Lynx1促进了梗死周围区域的突触聚集,并增加了树突棘周转率,这是记忆形成的新兴结构基础。正如预期,抑制Lynx1改善了卒中后慢性期的自发运动恢复和康复疗效。此外,我们开发了靶向Lynx1的反义寡核苷酸,发现其在卒中后慢性期给药可增强康复疗效。这些发现表明,梗死周围区域的树突棘动力学通过调节簇状棘形成,是决定康复反应性的关键因素,且Lynx1可能代表增强卒中后树突可塑性的有前景的治疗靶点。
The development of advanced therapies for stroke, spinal cord injury, and neurodegenerative diseases-primary causes of death, disability and dementia-requires a comprehensive understanding of the interplay between excitotoxicity, aberrant neurotrophic-signalling, glial reactivity, and neuroinflammation. Recent evidence has identified the truncated neurotrophin receptor TrkB-T1 as a potential master regulator of these processes. TrkB-T1 levels increase after stroke whereas the pro-survival full-length isoform (TrkB-FL) decreases. Furthermore, stroke-induced excitotoxicity triggers TrkB-T1 regulated intramembrane proteolysis (RIP), which produces TrkB-T1-ICD, a poorly characterised fragment containing the receptor intracellular domain and a few transmembrane amino acids. This study investigated whether the TrkB-T1 intracellular domain intrinsically contributes to neurotoxicity, reactive gliosis, and neuroinflammation. Our results predict that TrkB-T1 RIP generates a nuclear localization signal in TrkB-T1-ICD that might support nuclear translocation and injury-induced transcriptional regulation in neurons undergoing excitotoxicity. Using cell-penetrating peptides (CPPs), we generated a TrkB-T1-ICD mimetic peptide (Bio-LTT1Ct) containing the TrkB-T1 intracellular region. Bio-LTT1Ct translocated to the nucleus of neurons and astrocytes, provoking cell death and inducing early transcriptional changes in neurons, resembling those triggered by excitotoxicity. In vivo, intranasally administrated Bio-LTT1Ct was brain-permeable and distributed within cortical neurons and astrocytes across both hemispheres. Notably, Bio-LTT1Ct administration was sufficient to promote TrkB isoform imbalance, glial reactivity, and acquisition of proinflammatory profiles, all considered stroke hallmarks. In conclusion, these results imply that TrkB-T1 RIP might be a central mechanism of ischaemic damage and identify the receptor's intracellular region as sufficient to recapitulate stroke-like effects, marking this pathological mechanism as a critical target for therapy.
中文摘要:开发针对脑卒中、脊髓损伤和神经退行性疾病的先进疗法,需要全面理解兴奋性毒性、异常神经营养信号传导、胶质细胞反应性和神经炎症之间的相互作用。近期证据表明,截短的神经营养因子受体TrkB-T1可能是这些过程的主要调节因子。脑卒中后TrkB-T1水平升高,而促存活的完整长度异构体(TrkB-FL)降低。此外,脑卒中诱导的兴奋性毒性触发TrkB-T1调控的膜内蛋白水解(RIP),产生TrkB-T1-ICD,这是一种含有受体胞内结构域和少量跨膜氨基酸的特征尚不明确的片段。本研究探讨了TrkB-T1胞内结构域是否内在性地促进神经毒性、反应性胶质增生和神经炎症。我们的结果预测,TrkB-T1 RIP在TrkB-T1-ICD中产生核定位信号,可能支持核易位及神经元兴奋性毒性下的损伤诱导转录调控。利用细胞穿透肽(CPPs),我们构建了含有TrkB-T1胞内区域的TrkB-T1-ICD模拟肽(Bio-LTT1Ct)。Bio-LTT1Ct易位至神经元和星形胶质细胞的细胞核,引发细胞死亡并诱导神经元早期转录变化,类似于兴奋性毒性触发的变化。体内实验中,鼻内给药的Bio-LTT1Ct具有脑渗透性,分布在双侧大脑皮层的神经元和星形胶质细胞中。值得注意的是,Bio-LTT1Ct的给药足以促进TrkB异构体失衡、胶质细胞反应性以及获得促炎表型,这些均被视为脑卒中的标志。总之,这些结果暗示TrkB-T1 RIP可能是缺血损伤的核心机制,并确定该受体的胞内区域足以重现类似脑卒中的效应,将此病理机制标记为治疗的关键靶点。
4冠心病 (4篇)
临床研究 (3篇)
Photon-counting detector computed tomography (PCD-CT) is an emerging advanced CT technology that differs from conventional energy-integrating detector CT (EID-CT) scanners in its ability to directly convert incident X-ray photon energies into electrical signals. Since its commercial market introduction in 2021, several studies have identified advantages of this new technology in the field of cardiovascular imaging, including improved image quality due to an enhanced contrast-to-noise ratio, superior spatial resolution, reduced artefacts, and a reduced radiation dose. Nonetheless, radiation exposure with PCD-CT can vary depending on the acquisition mode and protocol used, highlighting the importance of tailored optimization in clinical practice. In particular, this new technology appears feasible in patients with a high plaque burden independent of morphology, unravelling new phenotypes of plaque, in patients with stents due to the improved visualization of the coronary in-stent lumen, potentially expanding the scope of CT. Early studies and clinical experience support these potential applications of PCD-CT in cardiovascular diagnostics, suggesting workflow optimization and improved patient management. In this review, the authors aim to describe the role of PCD-CT not only in the exclusion of coronary artery disease, grading of coronary stenosis and plaque imaging, but also in evaluation of cardiac chambers and myocardium for tissue characterization trying to understand whether PCD-CT has yet led to a true revolution and significant progress in cardiovascular imaging.
中文摘要:光子计数探测器计算机断层扫描(PCD-CT)是一项新兴的高级CT技术,其与传统能量积分探测器CT(EID-CT)扫描仪不同,能够直接将入射X射线光子能量转换为电信号。自2021年进入商业市场以来,多项研究已发现该新技术在心血管成像领域具有优势,包括因对比噪声比提高而改善的图像质量、优越的空间分辨率、伪影减少以及辐射剂量降低。尽管如此,PCD-CT的辐射暴露量会根据所使用的采集模式和方案而变化,这凸显了临床实践中进行个性化优化的重要性。特别是对于斑块负荷高且形态复杂的患者,该技术显示出可行性,能够揭示斑块的新的表型;对于支架植入患者,由于冠状动脉支架内管腔的可视化得到改善,其应用范围可能得到扩展。早期研究和临床经验支持PCD-CT在心血管诊断中的这些潜在应用,表明工作流程优化和患者管理得到了改善。在本综述中,作者旨在描述PCD-CT在排除冠心病、分级冠状动脉狭窄和斑块成像中的作用,以及在评估心脏腔室和心肌以进行组织表征方面的作用,试图理解PCD-CT是否已在心血管成像领域带来真正的革命和显著进展。
Reversing initial gains realized in the 1990s-2010s, coronary artery disease rates are now increasing and represent the dominant cause of death in many parts of the world. In recent years, substantive advances in non-invasive and invasive structural-based imaging techniques that delineate atheroma burden and anatomical composition have increased understanding of the pathogenesis of atherosclerosis. Driven by advances in imaging agent and hardware technology, the burgeoning field of molecular imaging has enabled clinical visualization of molecules and cells that underpin atherosclerosis pathobiology. Integrating the molecular and anatomical measures of atherosclerosis has promoted a deeper understanding of disease progression, patient-specific risk, and the effects of atherosclerosis pharmacotherapeutics and devices. With the great recognition of the role of inflammation as a residual risk marker of adverse outcomes for coronary artery disease patients, cellular and molecular imaging of inflammation and other disease activities is positioned to usher in a new era of risk assessment and personalized medical and interventional therapeutics for atherosclerosis patients. Moreover, molecular imaging offers the potential for assessing the actions of interventions on atherogenic processes, validating effects in vivo, and possibly informing optimal dose selection and treatment duration. This review will present the state-of-the-art in coronary artery disease cellular and molecular imaging and provide a roadmap for near-term translational and clinical applications.
中文摘要:逆转了二十世纪九十年代至二十一世纪十年间取得的初步成果,冠状动脉疾病发病率目前呈上升趋势,并已成为全球许多地区的主要死因。近年来,在描绘斑块负荷和解剖组成的无创及有创结构成像技术方面取得了实质性进展,加深了对动脉粥样硬化发病机制的理解。受成像剂和硬件技术进步驱动,分子成像这一新兴领域实现了对支撑动脉粥样硬化病理生物学的分子和细胞的临床可视化。整合动脉粥样硬化的分子和解剖学指标促进了对疾病进展、患者特异性风险以及动脉粥样硬化药物治疗和器械效果的更深入理解。鉴于炎症作为冠状动脉疾病患者不良结局残余风险标志物的作用得到广泛认可,针对炎症及其他疾病活动的细胞和分子成像有望为动脉粥样硬化患者开启风险评估及个性化医疗和介入治疗的新纪元。此外,分子成像提供了评估干预措施对致动脉粥样硬化过程作用的潜力,验证体内效果,并可能为最佳剂量选择和疗程提供依据。本综述将展示冠状动脉疾病细胞和分子成像的最新进展,并为近期的转化和临床应用提供路线图。
Inflammation is an essential physiological process that preserves host homeostasis, yet chronic inflammation is now recognized as a common pathological basis of many diseases. In coronary artery disease (CAD), chronic inflammation is central to the initiation and progression of atherosclerosis. Accordingly, anti-inflammatory therapy has emerged as a major focus of investigation in this field. Although multiple inflammatory pathways have been evaluated as therapeutic targets in clinical trials, strategies with demonstrated clinical benefit remain limited. In this review, we examine the sources of inflammation in CAD, approaches to inflammatory risk stratification, and advances in anti-inflammatory therapy. To explain divergent trial outcomes and guide future clinical translation, we propose a 4R framework: the right target, the right patient, the right timing, and the right benefit-risk balance. Anti-inflammatory treatment remains promising. Within this framework, refined inflammatory phenotyping and evaluation of stage-dependent efficacy represent immediate priorities for future trials.
中文摘要:炎症是维持宿主稳态的重要生理过程,然而慢性炎症现已被认为是许多疾病的共同病理基础。在冠状动脉疾病(CAD)中,慢性炎症是动脉粥样硬化发生和发展的核心环节。因此,抗炎治疗已成为该领域研究的主要焦点。尽管多项临床试验评估了多种炎症通路作为治疗靶点,但具有明确临床获益的策略仍然有限。本综述探讨了 CAD 中炎症的来源、炎症风险分层的方法以及抗炎治疗的进展。为了解释试验结果的差异并指导未来的临床转化,我们提出了一个四 R 框架:正确的靶点、正确的患者、正确的时机以及正确的风险收益平衡。抗炎治疗前景广阔。在此框架下,精细化的炎症表型分析和评估阶段依赖性疗效是未来试验的当务之急。
基础研究 (1篇)
Continuous monitoring of protein biomarkers could transform the management of acute and chronic diseases. Despite tremendous potential, wearable health monitors have remained largely limited to metabolites and small molecules. A key challenge is the limited availability of biointerfaces that reversibly track low-abundance proteins in vivo without user intervention. Here, we present the Differential Aptalyzer, a minimally invasive hydrogel microneedle platform for continuous monitoring of proteins in skin interstitial fluid. The platform combines high-affinity antibodies for selective target capture with aptamers for reversible electrochemical signal transduction. When integrated into a differential electrochemical chip and pulse-assisted sensor regeneration, this approach enables continuous monitoring of proteins in a wearable format. Using cardiac troponin I (cTnI) as a clinically relevant model analyte, Differential Aptalyzer offers a broad dynamic range (0.003 to 0.640 nanograms per milliliter) and strong specificity against interfering proteins. This platform reliably tracks both rising and falling exogenous cTnI levels injected into healthy mice, as well as endogenously elevated cTnI in a double-knockout mouse model of coronary artery disease, demonstrating its capability in continuous protein monitoring and identifying coronary artery disease cohorts.
中文摘要:蛋白质生物标志物的连续监测有望改变急慢性疾病的管理模式。尽管潜力巨大,可穿戴健康监测设备目前仍主要局限于代谢物和小分子。关键挑战在于缺乏无需用户干预即可在体内可逆追踪低丰度蛋白质的生物界面。本研究提出了一种名为差分适配体分析仪的微创水凝胶微针平台,用于连续监测皮肤间质液中的蛋白质。该平台结合了高亲和力抗体以实现选择性靶标捕获,以及适配体用于可逆的电化学信号转导。将其集成到差分电化学芯片中并结合脉冲辅助传感器再生技术,该方法实现了可穿戴格式下的蛋白质连续监测。以临床相关的模型分析物心肌肌钙蛋白I为例,差分适配体分析仪提供了宽动态范围(0.003至0.640纳克每毫升)以及对干扰蛋白的强特异性。该平台可靠地追踪了注入健康小鼠体内的外源性cTnI水平的升降,以及冠状动脉疾病双基因敲除小鼠模型中内源性升高的cTnI,证明了其在连续蛋白质监测及识别冠状动脉疾病队列方面的能力。
5心房颤动 (4篇)
临床研究 (3篇)
The incidence and risk factors for atrial arrhythmia (AA; atrial fibrillation and atrial flutter) in adults with systemic right ventricle (sRV), specifically congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries palliated with atrial switch procedures, are not well understood. This study aims to better define these risks. Adults with sRV presenting to Mayo Clinic between 2000 and 2022 were identified. Their clinical characteristics, electrocardiographic, and echocardiographic parameters at the time of first presentation were recorded. The incidence of sustained AA (>30 seconds) during follow-up was documented. Cox regression analysis was used to identify associations of incident atrial fibrillation/atrial flutter and mortality during follow-up. Among 447 patients with sRV (median age, 33.1 [24.6-42.8], 55.9% male, 247 cm3-TGA; 200 dextro-transposition of the great arteries postatrial switch), AA was present at first visit in 113 (25.3%). Out of the remaining 334 patients, new-onset AA occurred in 125 (37.4%) patients during a median follow-up of 11.1 years (interquartile range, 3.6-19.3). Isolated atrial fibrillation was observed in 89 (37.4%), isolated atrial flutter in 76 (31.9%), and both atrial fibrillation and atrial flutter in 73 (30.7%) patients. In multivariable analysis, the risk factors for incident AA included age (hazard ratio, 1.04 [1.03-1.06]; P<0.001), d-TGA (hazard ratio, 1.96 [1.00-3.85]; P=0.05), and QRS duration (hazard ratio, 1.01 [1.00-1.02]; P=0.02). AA was associated with hospitalization for heart failure in 19% of patients. Among those treated with anti-arrhythmic drugs and ablation, recurrence occurred in over 50% of patients. AA was not an independent predictor of mortality. AA occurred in more than half of this cohort with sRV, with risk increasing significantly after the third decade of life. Advancing age, dextro-transposition of the great arteries, and prolonged QRS duration were associated with increased risk of AA. Close monitoring for AA and early interventions are warranted in all adults with sRV.
中文摘要:成人系统性右心室(sRV)患者中房性心律失常(AA,包括心房颤动和心房扑动)的发病率及危险因素尚不明确,特别是先天性矫正型大动脉转位和大动脉转位经心房调转术后的患者。本研究旨在明确这些风险。研究纳入了2000年至2022年间就诊于Mayo Clinic的sRV成人患者,记录其首次就诊时的临床特征、心电图及超声心动图参数,并记录随访期间持续性AA(>30秒)的发生情况。采用Cox回归分析识别房颤/房扑发生及随访期间死亡率的关联因素。在447名sRV患者中(中位年龄33.1岁,男性占55.9%,其中247名为TGA,200名为大动脉转位术后心房调转),首次就诊时已有AA的患者为113例(25.3%)。在其余334名患者中,中位随访11.1年(四分位距3.6-19.3年)期间,新发AA的有125例(37.4%)。其中孤立性房颤89例(37.4%),孤立性房扑76例(31.9%),同时存在房颤和房扑73例(30.7%)。多变量分析显示,AA的危险因素包括年龄(风险比1.04 [1.03-1.06];P<0.001)、大动脉转位(风险比1.96 [1.00-3.85];P=0.05)和QRS波时限(风险比1.01 [1.00-1.02];P=0.02)。AA与19%的患者因心力衰竭住院相关。在接受抗心律失常药物和消融治疗的患者中,复发率超过50%。AA并非死亡率的独立预测因子。该sRV队列中超过一半的患者发生AA,且风险在第三十年后显著增加。高龄、大动脉转位和QRS波延长与AA风险增加相关。所有成人sRV患者均应密切监测AA并进行早期干预。
Guidelines recommend concomitant surgical ablation during cardiac surgery in patients with atrial fibrillation (AF). However, the optimal lesion set remains uncertain, with ongoing debate regarding the relative benefits and risks of biatrial versus left atrial (LA) maze ablation. In this multicenter, randomized, single-blind trial, patients with persistent or long-standing persistent AF undergoing rheumatic mitral valve surgery, with or without concomitant cardiac surgical procedures, were randomly assigned in a 1:1 ratio to undergo biatrial or LA maze ablation. The biatrial group underwent a complete Cox-Maze IV procedure; the LA group received a left-sided maze lesion set. To ensure standardization and consistency of the ablation procedures, surgeons underwent pretrial training and certification, and all procedures were videorecorded and centrally reviewed. The primary outcome was freedom from atrial tachyarrhythmias lasting >30 seconds without antiarrhythmic drugs within 12 months. The key secondary end point was freedom from permanent pacemaker implantation. All 323 randomized patients were included in the intention-to-treat analysis (mean age, 56.5 years; 72.1% women; mean LA diameter, 51.9 mm). At 12 months, 78.7% of patients (129 of 164) in the biatrial group and 68.6% (109 of 159) in the LA group were free from atrial tachyarrhythmias (adjusted difference, 10.7% [1-sided lower 95% CI, 3%]; P=0.01). Freedom from permanent pacemaker implantation was noted in 97.0% (159 of 164) of the biatrial group and 98.1% (156 of 159) of the LA group, meeting the predefined noninferiority criterion with a margin of -5% (adjusted difference, -1.1% [1-sided lower 95% CI, -3.9%]; Pnoninferiority=0.01). Among patients with persistent or long-standing persistent AF undergoing rheumatic cardiac valve surgery, biatrial maze ablation was superior to LA maze ablation in reducing recurrent atrial tachyarrhythmias, while maintaining noninferiority with respect to permanent pacemaker implantation. These findings provide direct evidence to inform lesion-set selection for surgical ablation during cardiac surgery. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05021601.
中文摘要:指南推荐心房颤动患者在心脏手术期间进行同期外科消融。然而,最佳病灶范围仍不确定,关于双心房迷宫消融与左心房迷宫消融的相对获益和风险仍存在争议。在这项多中心、随机、单盲试验中,接受风湿性二尖瓣手术(无论是否合并其他心脏外科手术)的持续性或长程持续性心房颤动患者被按1:1比例随机分配接受双心房或左心房迷宫消融。双心房组接受完整的Cox-Maze IV手术;左心房组接受左侧迷宫病灶范围。为确保消融程序的标准化和一致性,外科医生在试验前接受了培训和认证,所有程序均进行了视频记录并由中央审查。主要结局为12个月内无抗心律失常药物干预下持续时间大于30秒的心房快速性心律失常。关键次要终点为无需永久起搏器植入的比例。意向性治疗分析纳入了全部323名随机患者(平均年龄56.5岁;女性占72.1%;左心房平均直径51.9毫米)。在12个月时,双心房组129/164例(78.7%)和左心房组109/159例(68.6%)患者无心房快速性心律失常(调整差异为10.7% [单侧下限95%置信区间3%];P=0.01)。双心房组159/164例(97.0%)和左心房组156/159例(98.1%)患者无需永久起搏器植入,满足预设的非劣效性标准(边界为-5% [调整差异-1.1% [单侧下限95%置信区间-3.9%];P非劣效性=0.01])。在接受风湿性心脏瓣膜手术的持续性或长程持续性心房颤动患者中,双心房迷宫消融在减少复发性心房快速性心律失常方面优于左心房迷宫消融,同时在永久起搏器植入方面保持非劣效性。这些发现为心脏手术期间外科消融的病灶范围选择提供了直接证据。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT05021601
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with an increased risk of stroke, heart failure, mortality, and reduced quality of life. Although catheter ablation is the most widely used rhythm control strategy, its efficacy is limited in patients with non-paroxysmal atrial fibrillation and large left atria. To address this therapeutic gap, surgical approaches, including minimally invasive ablation, hybrid epicardial-endocardial strategies, and left atrial appendage exclusion, have continued to evolve. In this review, we focus on recent evidence to guide clinical decision-making on patient selection, advances in minimally invasive surgical and hybrid techniques, left atrial appendage exclusion, and postoperative anticoagulation management. Minimally invasive standalone Cox-Maze IV procedure and hybrid epicardial-endocardial ablation have demonstrated superior long-term freedom from atrial tachyarrhythmias compared with thoracoscopic epicardial surgical ablation or catheter ablation alone. Five-year arrhythmia-free survival has approached 85% to 95% in experienced centers after the Cox-Maze IV procedure and approximately 60% to 70% after hybrid ablation, compared with 35% to 45% after thoracoscopic epicardial ablation and 30% to 35% after single catheter ablation alone. Surgical left atrial appendage exclusion performed at the time of ablation may further reduce thromboembolic risk, although the optimal strategy for postprocedural anticoagulation remains uncertain. Careful patient selection remains essential, with atrial fibrillation type, duration, left atrial size, and previous treatment failure known to be key predictors of procedural success. As surgical techniques and supporting evidence continue to grow, standalone surgical ablation may assume a more important role in the contemporary management of atrial fibrillation, particularly for patients with advanced disease who are unlikely to achieve durable rhythm control with catheter ablation alone.
中文摘要:心房颤动是最常见的持续性心脏心律失常,与卒中、心力衰竭风险增加及死亡率升高和生活质量下降相关。尽管导管消融是最广泛使用的节律控制策略,但其在非阵发性心房颤动和左心房扩大患者中的疗效有限。为弥补这一治疗空白,包括微创消融、杂交心内膜-心外膜策略以及左心耳闭合在内的外科方法不断演进。本综述聚焦于近期证据,以指导关于患者选择、微创及杂交技术进展、左心耳闭合及术后抗凝管理的临床决策。与单独经胸镜心外膜消融或导管消融相比,独立的Cox-Maze IV术和杂交心内膜-心外膜消融显示出更优的长期心房快速性心律失常无复发性。在经验丰富的中心,Cox-Maze IV术后五年无心律失常生存率接近85%至95%,杂交消融后约为60%至70%,而经胸镜心外膜消融后为35%至45%,单独导管消融后为30%至35%。在消融同时行外科左心耳闭合可进一步降低血栓栓塞风险,尽管术后抗凝的最佳策略仍不确定。谨慎的患者选择至关重要,心房颤动类型、持续时间、左心房大小及既往治疗失败是已知的手术成功关键预测因素。随着外科技术及支持证据的不断增长,独立外科消融可能在当代心房颤动管理中发挥更重要作用,特别是对于难以仅通过导管消融获得持久节律控制的晚期疾病患者。
基础研究 (1篇)
Type 2 diabetes (T2DM) increases the risk of atrial fibrillation (AF). Elevated circulating ketone bodies (β-hydroxybutyrate [β-OHB]) in T2DM are considered hepatic in origin and benefit the heart via energy provision. Although we found ketogenesis enzyme Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) upregulated in both atrial and ventricular tissues of T2DM mice, alongside increased cardiac and circulating β-OHB. Whether enhanced Hmgcs2 is related to AF, ketogenesis-dependent or independent, remained unclear. T2DM mice were induced by high-fat diet and followed by streptozocin injection. Cardiac-specific Hmgcs2 overexpression and cardiomyocyte-specific Hmgcs2 knockout were conducted in T2DM mice. Cardiac function and left atrial diameter were evaluated using echocardiography, and cardiac electrophysiology was examined through electrical mapping. Programmed electrical stimulation was delivered to induce AF. Blood metabolomics from the coronary sinus and left atria of patients with or without T2DM were analyzed. The heart functioned as a primary ketogenic organ in T2DM mice via upregulating Hmgcs2, surpassing the liver. Hmgcs2-mediated shunting of fatty acid-derived acetyl-CoA into ketogenesis depleted myocardial energy reserves, exacerbated oxidative stress, and caused mitochondrial injury, ultimately increasing AF inducibility and diastolic dysfunction. In addition, cardiac-derived β-hydroxybutyrate released into circulation prolonged action potential duration in atrial cardiomyocytes. Mechanistically, Hmgcs2-mediated cytosolic β-hydroxybutyrylation targeted Oxct1 (3-oxoacid CoA-transferase 1) for degradation, blocking cardiac ketolysis. Blood metabolomics from the coronary sinus and left atria confirmed active cardiac ketogenesis in patients with T2DM and heart-derived ketone release into systemic circulation. Venous plasma β-OHB levels positively correlated with atrial low-voltage burden and postablation AF recurrence. Cardiomyocyte-specific Hmgcs2 knockdown improved cardiac utilization of fatty acids, β-OHB, and glucose in T2DM mice by suppressing cardiac ketogenesis; this intervention, with reduced circulating β-OHB, attenuated diabetes-associated AF. Cardiac Hmgcs2 represented a novel therapeutic target for diabetic AF and heart failure with preserved ejection fraction.
中文摘要:2型糖尿病增加心房颤动风险。2型糖尿病患者循环中升高的酮体(β-羟基丁酸)通常被认为源于肝脏,并通过提供能量对心脏有益。尽管我们发现2型糖尿病小鼠的心房和心室组织中Hmgcs2(3-羟基-3-甲基戊二酰辅酶A合成酶2)上调,且心脏及循环中的β-OHB增加,但Hmgcs2增强是否与心房颤动相关,以及是否依赖酮体生成仍不清楚。本研究通过高脂饮食联合链脲佐菌素注射诱导2型糖尿病小鼠模型,并在这些小鼠中进行了心脏特异性Hmgcs2过表达和心肌细胞特异性Hmgcs2敲除。利用超声心动图评估心脏功能和左心房直径,通过电生理标测检查心脏电生理特性,并通过程序电刺激诱导心房颤动。分析了有无2型糖尿病患者冠状静脉窦和左房血液代谢组学数据。结果显示,在2型糖尿病小鼠中,心脏通过上调Hmgcs2成为主要的酮体生成器官,其作用超过肝脏。Hmgcs2介导的脂肪酸衍生的乙酰辅酶A分流至酮体生成途径,耗竭了心肌能量储备,加剧氧化应激并导致线粒体损伤,最终增加心房颤动易感性和舒张功能障碍。此外,心脏来源的β-羟基丁酸释放入循环延长了心房心肌细胞的动作电位时程。机制上,Hmgcs2介导的胞质β-羟基丁酰化靶向Oxct1(3-氧代酸辅酶A转移酶1)导致其降解,从而阻断心脏酮体分解。冠状静脉窦和左房血液代谢组学证实了2型糖尿病患者存在活跃的心脏酮体生成及心脏来源酮体释放入全身循环。静脉血浆β-OHB水平与心房低电压负荷及消融后心房颤动复发呈正相关。心肌细胞特异性Hmgcs2敲低通过抑制心脏酮体生成,改善了2型糖尿病小鼠对脂肪酸、β-OHB和葡萄糖的心脏利用;该干预措施伴随循环β-OHB减少,减轻了糖尿病相关的心房颤动。心脏Hmgcs2代表了糖尿病性心房颤动及射血分数保留的心力衰竭的新型治疗靶点。
6卒中/脑血管 (3篇)
临床研究 (1篇)
Bariatric surgery and pharmacological weight-loss therapies improve cardiometabolic risk factors. However, direct head-to-head comparisons assessing their impact on cardiovascular outcomes remain limited. We performed an exploratory meta-analysis to compare bariatric surgery and pharmacological weight-loss therapies on major clinical outcomes in adults with obesity. A systematic literature search using PubMed and Scopus databases was conducted. Randomized and observational studies comparing bariatric surgery or incretin receptor agonists with controls were included in the analysis. The primary outcomes were all-cause mortality and MACE. A frequentist random-effects network meta-analysis was conducted across three nodes. A total of 40 studies, comprising more than 1.9 million patients, were included in the meta-analysis. Compared with control, bariatric surgery was associated with a significant reduction in all evaluated outcomes, including all-cause mortality (HR:0.57, 95%CI:0.51-0.65), MACE (HR:0.54, 95%CI:0.45-0.64), cardiovascular mortality, heart failure hospitalization, myocardial infarction, and stroke. Incretin receptor agonists were also associated with lower all-cause mortality (HR:0.62, 95%CI:0.52-0.74), lower MACE (HR:0.75, 95%CI:0.61-0.92) and reduced heart failure hospitalization. All-cause mortality-representing the most direct and clinically relevant endpoint-did not differ significantly between the two strategies in the exploratory network meta-analysis. Importantly, the network estimates should be cautiously interpreted, given the predominance of observational evidence, substantial heterogeneity, and very low confidence across all comparisons. Bariatric surgery and incretin receptor agonists are associated with substantial reductions in major cardiovascular outcomes in adults with obesity. In head-to-head comparisons, no significant differences were observed in all-cause mortality and stroke. Both strategies provide clinically meaningful benefits.
中文摘要:减重手术和药理学减重疗法可改善心血管代谢危险因素。然而,直接比较其对心血管结局影响的研究仍然有限。本研究进行了一项探索性荟萃分析,以比较减重手术和药理学减重疗法对肥胖成年人的主要临床结局的影响。通过PubMed和Scopus数据库进行系统文献检索。纳入随机研究和观察性研究,比较减重手术或肠促胰岛素受体激动剂与对照组的差异。主要结局指标为全因死亡率和主要不良心血管事件(MACE)。采用频率学随机效应网络荟萃分析对三个节点进行分析。共纳入40项研究,涉及超过190万患者。与对照组相比,减重手术与所有评估结局的显著降低相关,包括全因死亡率(HR:0.57,95%CI:0.51-0.65)、MACE(HR:0.54,95%CI:0.45-0.64)、心血管死亡率、心力衰竭住院、心肌梗死和中风。肠促胰岛素受体激动剂也与较低的全因死亡率(HR:0.62,95%CI:0.52-0.74)、较低的MACE(HR:0.75,95%CI:0.61-0.92)以及心力衰竭住院减少相关。在探索性网络荟萃分析中,全因死亡率作为最直接且临床相关的终点指标,两种策略之间无显著差异。重要的是,鉴于观察性证据占主导地位、异质性较大以及所有比较的置信度极低,应对网络估计值谨慎解读。减重手术和肠促胰岛素受体激动剂与肥胖成年人主要心血管结局的大幅降低相关。在直接比较中,全因死亡率和中风未观察到显著差异。两种策略均提供了具有临床意义的益处。
基础研究 (2篇)
Mitochondria are central hubs of intracellular Ca2+ signaling, sensing, integrating, and responding to cytosolic Ca2+ transients through tightly regulated uptake and efflux pathways. Despite its fundamental role in cellular physiology, the mechanisms by which mitochondrial Ca2+ signaling contributes to tissue-specific pathologies remain poorly understood. Disruption of this ancient and ubiquitous process can lead to various disease phenotypes, including neurological disorders, stroke, heart failure, diabetes, and liver disease. This review highlights how extensive heterogeneity in the molecular composition, regulation, and spatial organization of mitochondrial Ca2+ signaling machinery underlies these pleiotropic outcomes. Physiological insights are examined alongside systems-level approaches, such as comparative genomics, evolutionary analyses, and protein-protein interaction mapping, to reveal context-specific architectures of mitochondrial Ca2+ signaling. Collectively, these advances provide a framework for understanding how mitochondrial Ca2+ uptake and efflux pathways are tailored to organ-specific functions and vulnerabilities.
中文摘要:线粒体是细胞内钙信号的中心枢纽,通过严格调控的摄取和流出途径感知、整合并响应胞质钙瞬变。尽管其在细胞生理中发挥基础作用,但线粒体钙信号机制如何促成组织特异性病理过程仍知之甚少。这一古老且普遍存在的进程一旦受到破坏,可导致多种疾病表型,包括神经系统疾病、卒中、心力衰竭、糖尿病和肝病。本综述强调了线粒体钙信号机器在分子组成、调控及空间组织方面的广泛异质性是这些多效性结果的潜在基础。研究结合生理见解与系统级方法(如比较基因组学、进化分析及蛋白质相互作用图谱绘制),揭示了线粒体钙信号的组织特异性架构。综上所述,这些进展为理解线粒体钙摄取和流出通路如何适应器官特异性功能及脆弱性提供了框架。
Ingestible capsules have garnered considerable attention due to their high gastrointestinal (GI) transitability and minimally invasive nature. However, constrained by pill-sized dimensions (approximately 2 to 4 cubic centimeters), current ingestible capsules face persistent challenges in achieving both controllable high mechanical output and sufficient onboard power delivery, limiting their capacity for effective in vivo therapeutic interventions. Here, we present a wirelessly powered ingestible electronic capsule that integrates programmable soft phase-change actuation within a rigid-soft architecture to enable programmable, high-output mechanical operations. Leveraging bidirectional thermoelectric regulation and guided rigid-soft coupling, the capsule delivers a peak force of 3.8 newtons and a volumetric stroke of ∼250 cubic millimeters within a confined geometry based on the phase-change actuation. To power this actuation, we implemented a compact wireless power transfer system that achieved a maximum load-received power per unit receiver-coil volume of 9.15 watts per cubic centimeter at a 5-centimeter transfer distance under the tested conditions. The structural adaptability of the soft actuator allows modular integration of functional end-effectors, supporting high-output tissue acquisition, site-directed delivery of model liquid or gel payloads, and active biofluid sampling under magnetic navigation. In vivo experiments in beagles demonstrated the feasibility of mechanical interventions in physiological environments. By overcoming the long-standing power and actuation constraints of capsule architecture, this work establishes a physical framework for high-output ingestible robotics and advances the development of minimally invasive robotic platforms for complex GI interventions.
中文摘要:可吞服胶囊因其高胃肠道通过性和微创特性而备受关注。然而,受限于药丸尺寸(约2至4立方厘米),现有的可吞服胶囊在实现可控的高机械输出和充足的机载电力输送方面仍面临持续挑战,限制了其在体内治疗干预中的有效性。本文提出了一种无线供电的可吞服电子胶囊,该胶囊在刚柔耦合架构中集成了可编程的软相变驱动机制,以实现可编程、高输出的机械操作。利用双向热电调节和引导式刚柔耦合技术,该胶囊基于相变驱动在受限几何空间内提供了3.8牛顿的峰值力和约250立方毫米的体积行程。为驱动此动作,我们实现了一个紧凑的无线能量传输系统,在测试条件下,以5厘米传输距离实现了每单位接收线圈体积9.15瓦的最大负载接收功率。软执行器的结构适应性支持功能末端执行器的模块化集成,从而在磁导航支持下支持高输出组织获取、模型液体或凝胶载荷的位点定向递送以及主动生物流体采样。比格犬体内的实验证明了机械干预在生理环境中的可行性。通过克服胶囊架构长期存在的电力和驱动限制,本研究为高输出可吞服机器人建立了物理框架,并推动了用于复杂胃肠道干预的微创机器人平台的发展。
7心肌病/心肌炎 (3篇)
临床研究 (2篇)
Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56-69) to 87 (interquartile range, 82-92; P<0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0-66.6 mL) to 70.8 mL (interquartile range, 61.3-82.3 mL; P<0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min (P=0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 13N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 (P=0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05648825.
中文摘要:无梗阻型肥厚型心肌病(nHCM)定义为无左室流出道梗阻的肥厚型心肌病,因其病理生理机制异质性,治疗仍具挑战性。本研究评估了经心尖跳动心脏室间隔切除术在症状性nHCM患者中的安全性和有效性。对具有症状且药物难治性的nHCM患者进行前瞻性入组,通过左侧小切口行经心尖跳动心脏室间隔切除术。在实时经食管超声心动图引导下,定制化切除室间隔以缓解收缩期腔室闭塞和中部至心尖部室梗阻,并扩大左室腔。主要终点为术后6至12个月的手术成功率,定义为与基线相比满足所有预设标准:纽约心脏病协会(NYHA)功能分级改善≥1级,堪萨斯城心肌病问卷(KCCQ)评分增加≥10分,每搏输出量增加≥10 mL,以及正常或I级舒张功能。2023年1月至2025年1月,同济医院共有97名符合条件的nHCM患者接受了经心尖跳动心脏室间隔切除术。术后6至12个月时,手术成功率为87.6%。具体而言,NYHA功能分级I级从基线的0%增至随访期的93.8%,KCCQ评分中位数从64(四分位距56-69)改善至87(四分位距82-92;P<0.001),每搏输出量从53.5 mL(四分位距41.0-66.6 mL)增至70.8 mL(四分位距61.3-82.3 mL;P<0.001),正常或I级舒张功能比例从65.6%增至97.9%。在接受配对心肺运动试验的患者中(n=58),峰值摄氧量增加1.1±2.9 mL/kg/min(P=0.008)。在对12名接受配对13N-氨正电子发射断层扫描患者的探索性假设生成分析中,冠状动脉血流储备从1.8±0.3增至2.0±0.4(P=0.034)。不良事件包括二尖瓣损伤(n=1)和室间隔穿孔(n=1),后者导致1例术后死亡。经心尖跳动心脏室间隔切除术与左室几何重构的有利改变及症状、健康状况和功能能力的显著改善相关,适用于部分症状性nHCM患者。作为此前难治人群的一种潜在治疗选择,值得在控制性的多中心研究中进一步评估。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT05648825。
A major challenge in dilated cardiomyopathy (DCM) care is the identification and management of individuals at risk before disease manifestation. An artificial intelligence (AI) model applied to electrocardiography (ECG) was developed to detect and predict the echocardiographic DCM phenotype (left ventricular dilatation with systolic dysfunction) and was evaluated for its ability to stratify the risk of incident DCM in familial cohorts. A deep learning model was trained to detect the echocardiographic DCM phenotype and to predict its future onset, using more than 330 000 ECG-echocardiogram pairs from the Beth Israel Deaconess Medical Center, Boston. Model performance was validated in cohorts from the UK Biobank, Zhongshan Hospital, and Antwerp University Hospital, and compared with models based on traditional ECG features and echocardiographic traits. To assess performance in familial DCM, genetically predisposed individuals identified through cascade screening at the cardiogenetics clinics of Antwerp University Hospital (n = 166, 18% DCM positive) and Maastricht University Medical Center (n = 177, 18% DCM positive) were evaluated. The AI-ECG model achieved areas under the receiver operating characteristic curve of .87-.97 for diagnosing the prevalent DCM phenotype, outperforming traditional ECG parameters. AI-ECG was comparable to echocardiography for predicting future DCM (C-index .80-.87 and .80-.90, respectively). In familial cohorts, 5-year negative predictive values were 95.5% (Antwerp) and 91.5% (Maastricht), with corresponding positive predictive values of 42.4% and 39.4%, while high-risk scores were associated with a 5.1-6.4-fold increased risk of incident DCM. The explainable AI-ECG model detects the echocardiographic DCM phenotype and predicts future disease, and supports the exclusion of short- to mid-term disease in genetically at-risk individuals. This low-cost tool could help reduce surveillance burden and facilitate earlier intervention.
中文摘要:扩张型心肌病(DCM)护理的主要挑战在于疾病显现前识别和管理高风险个体。本研究开发了一种应用于心电图(ECG)的人工智能(AI)模型,用于检测并预测超声心动图定义的DCM表型(左心室扩大伴收缩功能障碍),并评估其在家族队列中分层新发DCM风险的能力。该深度学习模型利用来自波士顿贝斯以色列女执事医疗中心超过33万对ECG-超声心动图数据进行了训练,以检测超声心动图DCM表型并预测其未来发病。模型性能在英国生物样本库、中山医院和安特卫普大学医院队列中进行了验证,并与基于传统ECG特征和超声心动图特征的模型进行了比较。为评估其在家族性DCM中的表现,对通过安特卫普大学医院(n=166,18% DCM阳性)和马斯特里赫特大学医学中心(n=177,18% DCM阳性)心脏遗传学诊所进行级联筛查确定的遗传易感个体进行了评估。AI-ECG模型在诊断现患DCM表型时的受试者工作特征曲线下面积(AUC)为0.87-0.97,优于传统ECG参数。AI-ECG在预测未来DCM方面与超声心动图相当(C指数分别为0.80-0.87和0.80-0.90)。在家族队列中,5年阴性预测值分别为安特卫普的95.5%和马斯特里赫特的91.5%,相应的阳性预测值为42.4%和39.4%,而高风险评分与新发DCM风险增加5.1-6.4倍相关。可解释的AI-ECG模型能够检测超声心动图DCM表型并预测未来疾病,支持在遗传高危个体中排除短至中期疾病。这种低成本工具有助于减少监测负担并促进早期干预。
基础研究 (1篇)
Inherited cardiomyopathies are the leading cause of heart failure in young adults, with limited therapeutic options. Desmin-related cardiomyopathy (DRM), caused by mutations to cytoskeletal proteins and their chaperones, exemplifies this challenge: Here, protein quality control is compromised, leading to toxic protein aggregates that destroy cardiomyocyte contractile machinery. One of the deadliest DRM mutations in the chaperone protein αB crystallin (CRYAB-R120G) lacks a genetically matched preclinical model: Mouse models require massive overexpression of mutant CRYAB, raising questions about physiological relevance. Here, we establish a human model of CRYAB-linked DRM, using induced pluripotent stem cells expressing CRYAB-R120G at near-endogenous levels. We show that three-dimensional mechanical loading, but not fatty acid-based metabolic maturation media, is essential for expressing Desmin, whose aggregation defines DRM. Using microengineered heart tissues, we found that contractile deficits are associated with impaired calcium handling, pointing to electromechanical uncoupling in DRM. Treatment with the Janus kinase 1 inhibitor itacitinib partially rescued contractility, providing a functional validation of this emerging therapeutic strategy.
中文摘要:遗传性心肌病是年轻人心力衰竭的主要原因,且治疗选择有限。由细胞骨架蛋白及其伴侣蛋白突变引起的Desmin相关心肌病(DRM)即为此类挑战的典型代表:在此类疾病中,蛋白质质量控制受损,导致毒性蛋白聚集体破坏心肌细胞的收缩机制。伴侣蛋白αB-晶体蛋白(CRYAB-R120G)的一种最致命的DRM突变缺乏基因匹配的临床前模型:小鼠模型需要大量过表达突变型CRYAB,这引发了关于其生理相关性的疑问。在此,我们建立了一种人类CRYAB连锁DRM模型,使用在接近内源性水平表达CRYAB-R120G的诱导多能干细胞。我们表明,三维机械负荷而非基于脂肪酸的代谢成熟培养基对于表达定义DRM的Desmin至关重要。利用微工程心脏组织,我们发现收缩缺陷与钙处理受损有关,指向DRM中的电机械解耦。使用Janus激酶1抑制剂Itacitinib治疗部分挽救了收缩力,为该新兴治疗策略提供了功能验证。
8心肌梗死 (2篇)
基础研究 (2篇)
Following myocardial infarction (MI), excessive inflammation and maladaptive fibrosis synergistically drive adverse cardiac remodeling and progressive functional deterioration. Current therapeutic strategies targeting these pathological processes individually have shown limited efficacy, highlighting the need for approaches that coordinately regulate the post-infarction microenvironment. Here, we report an infarct-targeted nanoparticle platform for dual-target modulation of inflammatory and fibrotic signaling after MI. A bifunctional peptide, RYTVELAGGGGGPLGMWSRGGGGGECGLLPVGRPDRNVWRWLCK (RPE), was engineered by integrating a pathway-selective IL-1 receptor-targeting immunomodulatory domain and a TGF-β receptor II-targeting antifibrotic domain through a matrix metalloproteinase (MMP)-cleavable linker. Intact RPE possesses both anti-inflammatory and anti-fibrotic activities, while its MMP-responsive linker renders RPE susceptible to cleavage by the upregulated MMPs in the infarcted myocardium into the RYT and ECG domains, which can independently modulate IL-1 and TGF-β signaling, respectively. To allow rapid and safe delivery during the critical therapeutic window following MI (acute phase), RPE was encapsulated into intravenously deliverable, infarcted heart-targeting nanoparticles, enabling preferential accumulation and sustained release within the injured myocardium. In a mouse MI model, this platform significantly attenuated inflammatory responses, reduced myofibroblast formation and fibrotic remodeling, and enhanced neovascularization, resulting in marked improvement in cardiac function. These findings demonstrate an infarcted heart-targeting nanotherapeutic strategy for cardiac repair after acute MI through dual-target modulation of post-infarction inflammation and fibrosis. STATEMENT OF SIGNIFICANCE: Effective treatment of myocardial infarction remains challenging because excessive inflammation and fibrosis occur simultaneously but require coordinated regulation during the acute phase after injury. We developed a spatiotemporally controlled nanotherapeutic platform that combines infarcted heart-targeting nanoparticles with a microenvironment-responsive bifunctional peptide. Elevated matrix metalloproteinase activity in the infarcted myocardium activates the peptide, enabling site-specific and independent modulation of IL-1- and TGF-β-mediated inflammatory and fibrotic signaling. Intravenous delivery allows rapid treatment without direct myocardial injection while providing sustained therapeutic release in injured tissue. This strategy significantly improves cardiac repair by reducing inflammation and fibrosis, enhancing neovascularization, and improving cardiac function, providing a promising biomaterial-based approach for precision therapy after myocardial infarction.
中文摘要:心肌梗死后,过度的炎症与适应性不良的纤维化协同驱动不良心脏重构及进行性功能恶化。针对这些病理过程单独干预的现有治疗策略疗效有限,凸显了需要协调调控梗死后微环境的方法。本研究报道了一种用于双靶点调节心肌梗死后炎症与纤维化信号的心梗靶向纳米平台。通过基质金属蛋白酶可切割连接肽将通路选择性白细胞介素-1受体靶向免疫调节结构域与转化生长因子-β受体II靶向抗纤维化结构域整合,工程化设计了双功能肽RYTVELAGGGGGPLGMWSRGGGGGECGLLPVGRPDRNVWRWLCK(RPE)。完整RPE兼具抗炎与抗纤维化活性,而其MMP响应性连接肽使RPE易受梗死心肌中上调的基质金属蛋白酶切割为RYT和ECG结构域,从而分别独立调节IL-1和TGF-β信号。为实现心肌梗死后关键治疗窗口(急性期)的快速安全递送,将RPE封装于可静脉注射的心梗靶向纳米颗粒中,实现损伤心肌中的优先蓄积与持续释放。在小鼠心肌梗死模型中,该平台显著减弱炎症反应,减少肌成纤维细胞形成及纤维化重构,增强新生血管生成,从而显著改善心脏功能。这些发现证明了一种通过双靶点调节梗死后炎症与纤维化来实现急性心肌梗死后心脏修复的心梗靶向纳米治疗策略。有效治疗心肌梗死仍具挑战性,因为过度的炎症与纤维化同时发生但需在损伤后急性期进行协调调控。我们开发了一种时空控制的纳米治疗平台,将心梗靶向纳米颗粒与环境响应性双功能肽相结合。梗死心肌中升高的基质金属蛋白酶活性激活该肽,实现IL-1和TGF-β介导的炎症与纤维化信号的位点特异性独立调节。静脉给药允许快速治疗而无需直接心肌注射,同时在损伤组织中提供持续的治疗释放。该策略通过减少炎症与纤维化、增强新生血管生成及改善心脏功能显著促进心脏修复,为心肌梗死后精准治疗提供了有前景的生物材料方法。
Hepatic disorders frequently coexist with cardiovascular diseases, leading to worsened prognosis. However, the mechanisms of inter-organ communication and the impact of historical hepatic injury await elucidation. Here, we report that the historical liver damage triggers long-term reprogramming of the innate immune system, biases hematopoietic stem cells differentiation toward myeloid fate, and aggravates inflammatory injury during myocardial infarction (MI). This immune memory is transmissible in bone marrow transplantation and parabiosis models. Injured liver-derived palmitic acid is responsible for the metabolic rewiring of cardiac macrophages during memory formation and establishes persistent epigenetic signatures in the transcriptional regulatory regions of hepatic injury-associated memory ("HepMem") genes containing the activator protein-1 motif. The HepMem monocyte/macrophages are expanded in liver-injured mice and potentiate the post-MI inflammatory cascades and adverse cardiac remodeling. Therefore, the innate immune memory links the past hepatic injury with MI, guiding the promising therapeutic approaches for the inflammatory cardiac comorbidities.
中文摘要:肝脏疾病常与心血管疾病共存并导致预后恶化,但器官间通讯机制及既往肝损伤的影响尚待阐明。本研究报道既往肝损伤可触发先天免疫系统的长期重编程,促使造血干细胞向髓系命运分化,并在心肌梗死(MI)期间加重炎症性损伤。该免疫记忆在骨髓移植和连体共生模型中均可传递。受损肝脏来源的棕榈酸负责记忆形成过程中心脏巨噬细胞的代谢重编程,并在含有激活蛋白-1基序的肝损伤相关记忆(HepMem)基因转录调控区建立持久的表观遗传特征。HepMem单核/巨噬细胞在肝损伤小鼠中扩增,并增强MI后的炎症级联反应及不良心脏重构。因此,先天免疫记忆将既往肝损伤与MI联系起来,为治疗炎症性心脏合并症提供了有前景的治疗方向。
9肺动脉高压 (1篇)
基础研究 (1篇)
Pulmonary hypertension (PH) is frequently complicated by coronary artery remodeling and dysfunction, yet the underlying mechanisms remain poorly defined. This study investigated whether and how chronic hypoxia drives coronary artery dysfunction through TRPC3/4-mediated Ca²⁺ influx and cGAS-STING activation in smooth muscle cells (SMCs). A rat model of PH was established by exposure to chronic hypoxia. Coronary artery structure and function were assessed by histology and wire myography. In vitro experiments were performed using cultured SMCs, with molecular and cellular analyses including qPCR, western blotting, immunofluorescence, live-cell imaging, mitochondrial assays, and cell-free phase separation assays. PH rats exhibited increased coronary TRPC3/4 expression, enhanced Ca²⁺ influx, and coronary hypercontractility. In cultured SMCs, hypoxia induced mitochondrial dysfunction, mtDNA release, and cGAS condensate formation. TRPC3/4-mediated Ca²⁺ overload promoted mitochondrial damage and cGAS phase separation, while STIM1/ORAI1-mediated store-operated Ca²⁺ entry (SOCE) further contributed to STING activation. Cell-free assays demonstrated that Ca²⁺ promoted cGAS phase separation in both the presence and absence of dsDNA, and this effect was dependent on the cGAS intrinsically disordered region (IDR). Importantly, CIP3 attenuated cGAS phase separation and downstream STING signaling, thereby mitigating hypoxia-induced SMC proliferation, migration, and phenotypic switching. In PH rats, short-term treatment with VAPG-targeted CIP3 reduced right ventricular systolic pressure, attenuated pulmonary and coronary vascular remodeling, and improved coronary contractile responses. Our findings establish a novel mechanistic axis wherein chronic hypoxia drives coronary artery dysfunction via TRPC3/4-mediated Ca²⁺ influx and phase separation-dependent cGAS-STING activation. In our experimental models, targeting cGAS phase separation, particularly through IDR-directed intervention, may represent a promising therapeutic strategy for PH-associated vascular pathology.
中文摘要:肺动脉高压常并发冠状动脉重构与功能障碍,但其潜在机制尚不明确。本研究探讨了慢性缺氧是否及如何通过TRPC3/4介导的Ca²⁺内流和cGAS-STING激活在平滑肌细胞中驱动冠状动脉功能障碍。通过慢性缺氧暴露建立大鼠肺动脉高压模型,利用组织学和微血管肌动图评估冠状动脉结构与功能。体外实验采用培养的平滑肌细胞,进行qPCR、Western blotting、免疫荧光、活细胞成像、线粒体检测及无细胞相分离分析等分子与细胞学分析。肺动脉高压大鼠表现出冠状动脉TRPC3/4表达增加、Ca²⁺内流增强及冠状动脉高反应性。在培养的平滑肌细胞中,缺氧诱导线粒体功能障碍、mtDNA释放及cGAS凝聚体形成。TRPC3/4介导的Ca²⁺超载促进线粒体损伤和cGAS相分离,而STIM1/ORAI1介导的储存操纵钙内流进一步促进STING激活。无细胞实验表明,无论是否存在双链DNA,Ca²⁺均促进cGAS相分离,且该效应依赖于cGAS内在无序区。重要的是,CIP3减弱了cGAS相分离及下游STING信号传导,从而减轻缺氧诱导的平滑肌细胞增殖、迁移和表型转换。在肺动脉高压大鼠中,短期使用靶向VAPG的CIP3治疗降低了右心室收缩压,减轻了肺部和冠状动脉血管重构,并改善了冠状动脉反应性。本研究确立了一个新的机制轴,即慢性缺氧通过TRPC3/4介导的Ca²⁺内流和相分离依赖的cGAS-STING激活驱动冠状动脉功能障碍。在实验模型中,靶向cGAS相分离,特别是通过针对内在无序区的干预,可能成为治疗肺动脉高压相关血管病变的有前景策略。
10心血管病 (1篇)
临床研究 (1篇)
The extent to which blood pressure (BP) and arterial stiffness mediate the association between long-term PM2.5 exposure and cardiovascular risk, and whether individuals with metabolic impairment are more susceptible, remain unclear. Within the "Risk of Cardiovascular diseases and abdominal aortic Aneurysms in Varese" (RoCAV) cohort, we retained 2119 men aged 50-75 and free of coronary heart disease (CHD) and stroke at baseline; carotid-femoral Pulse Wave Velocity (cfPWV) was measured in a subset of 1015 using an automated oscillometer. Exposure was the 12-month mean PM2.5 concentration before baseline (EXPANSE models); outcome was incident major acute CHD or stroke (MACE), fatal or non-fatal. We estimated the mediating contribution of BP and cfPWV through Marginal Structural Models and Aalen survival models, with individual- and area-level confounders. In a median follow-up of 7.6 years, 178 MACE events occurred (rate=1155 per 100,000 person-years), and 76 (1086/100,000 p-y) in the cfPWV subset. Systolic BP, mean BP, brachial pulse pressure and cfPWV were highest in the most exposed. Each 1-µg/m3 increase in PM2.5 was associated with 151 (95%CI:21-282) additional MACE events per 100,000 p-y, of which 48 (95%CI:17-79) were mediated by cfPWV (mediated proportion: 32%). Systolic BP and brachial pulse pressure each mediated about 16% of the PM2.5-associated risk. The cfPWV-mediated effect was enhanced in men with impaired glucose (96;95%CI:38-155) and elevated LDL-cholesterol (88;95%CI:28-147). Large-artery stiffness substantially contributes to the MACE burden associated with chronic PM2.5 exposure, especially in men with metabolic impairment. Monitoring cfPWV may help incorporate environmental risk into cardiovascular prevention.
中文摘要:长期PM2.5暴露与心血管风险之间关联的血压和动脉僵硬度中介作用程度,以及代谢受损个体是否更易感仍不清楚。在「瓦雷泽心血管疾病和腹主动脉瘤风险」队列中,我们保留了基线时无冠心病和中风的2119名50至75岁男性;其中1015人的颈股脉搏波速度通过自动示波法测量。暴露因素为基线前12个月的平均PM2.5浓度;结局为首次发生的主要急性冠心病或中风事件(包括致死性和非致死性)。我们利用边际结构模型和Aalen生存模型,在控制个体和区域水平混杂因素后,估算血压和cfPWV的中介贡献。在中位随访7.6年间,共发生178例MACE事件(发生率每10万人年1155例),cfPWV亚组中为76例(每10万人年1086例)。最高暴露组的收缩压、平均血压、肱动脉脉压和cfPWV均最高。PM2.5每增加1微克/立方米,与每10万人年额外增加151例MACE事件相关,其中48例由cfPWV中介(中介比例32%)。收缩压和肱动脉脉压各中介了约16的PM2.5相关风险。在血糖受损和低密度脂蛋白胆固醇升高的男性中,cfPWV介导效应增强。大动脉僵硬度对慢性PM2.5暴露相关的MACE负担贡献显著,尤其在代谢受损男性中。监测cfPWV可能有助于将环境风险纳入心血管预防。
11脑卒中 (1篇)
临床研究 (1篇)
Daily physiological homoeostasis varies with time of day, following diurnal cycles partially regulated by the central autonomic network (CAN). Experimental studies suggest that acute ischaemic stroke disrupts these rhythms, impairing recovery, but translation to humans has been limited by the lack of robust methods to quantify diurnal phase shifts. We developed a framework that uses continuous heart rate data to characterise shifts in diurnal cardiac rhythms relative to the phase expected at a given time of day, providing a dynamic marker of heart-brain axis function. We applied this approach to retrospective data from patients with ischaemic stroke in the Charité-Universitätsmedizin Berlin Data Warehouse (DWC) and the MIMIC-III/IV cohorts, quantifying rhythm shifts and examining their associations with lesion size, location, and clinical outcomes. Stroke was associated with systematic disruption of diurnal cardiac cycles, with larger shifts associated with worse clinical scores, impaired short-term recovery, and higher mortality. Within the CAN, greater rhythm shifts corresponded to larger infarcts, indicating region-specific vulnerability. These findings identify diurnal cardiac rhythm shifts as a clinically accessible biomarker of heart-brain-axis function. Given the observational design, these associations are hypothesis-generating and require prospective validation. The Schilling Foundation and the Schilling Professorship, DFG EXC-2049/NeuroCure.
中文摘要:每日生理稳态随时间变化,遵循由中枢自主神经网络部分调节的昼夜节律。实验研究表明急性缺血性卒中会破坏这些节律并损害恢复,但由于缺乏量化昼夜相位偏移的可靠方法,其向人类临床的转化受到限制。我们开发了一种利用连续心率数据来表征相对于给定时间预期相位的昼夜心脏节律偏移的框架,从而提供反映心脑轴功能的动态标志物。我们将该方法应用于柏林夏里特大学医学中心数据仓库及MIMIC-III/IV队列中缺血性卒中患者的回顾性数据,量化了节律偏移并考察其与病灶大小、位置及临床结局的关联。卒中与昼夜心脏节律的系统性破坏相关,较大的偏移与较差的临床评分、短期恢复受损及更高死亡率相关。在中枢自主神经网络内,更大的节律偏移对应于更大的梗死面积,提示区域特异性易感性。这些发现将昼夜心脏节律偏移确定为心脑轴功能的一种临床可及的生物标志物。鉴于观察性研究设计,这些关联仅为生成假设,需前瞻性验证。本研究由Schilling基金会和Schilling讲席、DFG EXC-2049/NeuroCure资助。
12妊娠期高血压 (1篇)
基础研究 (1篇)
Biological aging is a fundamental driver of chronic disease, yet its role in the cause of preeclampsia and gestational hypertension remains poorly defined. We used a multimodal framework that triangulated genetic, epidemiological, and experimental approaches to assess the associations of biological aging with preeclampsia and gestational hypertension. Publicly available human and mouse transcriptomic data were analyzed to identify shared aging- and preeclampsia-associated signatures, while the potential of nicotinic acid to alleviate aging- and preeclampsia-related features was further evaluated in experimental models. Two-sample Mendelian randomization demonstrated that biological age acceleration was associated with higher odds of preeclampsia (odds ratio, 1.55 [95% CI, 1.22-1.96]; P=2.67×10-4) and gestational hypertension (odds ratio, 1.56 [95% CI, 1.12-2.19]; P=0.009), while positive genetic correlations were also observed for both outcomes. In the nested case-control study, higher early pregnancy biological age acceleration was consistently associated with preeclampsia risk in both primary (odds ratio, 1.16 [95% CI, 1.01-1.35]; P=0.047) and sensitivity (odds ratio, 1.14 [95% CI, 1.03-1.29]; P=0.042) analyses, with the associations persisting after covariate adjustment and exclusion of systolic blood pressure from biological age acceleration calculation. Mouse models exhibited preeclampsia-like features accompanied by concordant alterations in biological age-related biomarkers and telomere dysfunction. These changes were partially attenuated by nicotinic acid treatment, whereas placental organoids showed limited growth responses to nicotinic acid. Complementing these phenotypic observations, transcriptomic analyses identified shared aging- and preeclampsia-associated signatures across human and mouse data sets. Convergent evidence links biological aging with preeclampsia and gestational hypertension, particularly biological age acceleration with preeclampsia. Experimental findings provide complementary context but do not establish a specific mechanism or therapeutic role for nicotinic acid.
中文摘要:生物衰老是慢性疾病的根本驱动因素,但其在子痫前期和妊娠期高血压病因中的作用尚不明确。我们采用多模态框架,结合遗传学、流行病学和实验方法评估生物衰老与子痫前期及妊娠期高血压的关联。分析公开的人和小鼠转录组数据以鉴定共享的衰老和子痫前期相关特征,并在实验模型中进一步评估烟酸缓解衰老和子痫前期相关特征的潜力。两样本孟德尔随机化表明,生物年龄加速与子痫前期(比值比1.55 [95% CI, 1.22-1.96]; P=2.67×10-4)和妊娠期高血压(比值比1.56 [95% CI, 1.12-2.19]; P=0.009)的高几率相关,两种结局也观察到阳性遗传相关性。在嵌套病例对照研究中,较高的孕早期生物年龄加速始终与子痫前期风险相关,主要分析(比值比1.16 [95% CI, 1.01-1.35]; P=0.047)和敏感性分析(比值比1.14 [95% CI, 1.03-1.29]; P=0.042)均显示此关联,且在调整协变量及从生物年龄加速计算中排除收缩压后关联依然存在。小鼠模型表现出类似子痫前期的特征,伴随生物衰老相关生物标志物和端粒功能障碍的一致性改变。烟酸治疗部分减轻了这些变化,而胎盘类器官对烟酸的反应有限。表型观察补充了转录组分析结果,在人鼠数据集中鉴定出共享的衰老和子痫前期相关特征。汇聚证据将生物衰老与子痫前期和妊娠期高血压联系起来,特别是生物年龄加速与子痫前期的关联。实验发现提供了互补背景,但未确立烟酸的具体机制或治疗作用。
13冠心病/心绞痛 (1篇)
临床研究 (1篇)
Psychological stress and abnormal cardiovascular reactivity to mental stress are both associated with adverse outcomes in coronary artery disease (CAD), but their independent and combined prognostic significance remains unclear. We studied 648 participants with stable CAD from two prospective cohorts. A psychological distress score (PDS) was derived as a rank-based composite of depressive symptoms, anxiety, anger, perceived stress, and post-traumatic stress symptoms evaluated using questionnaires, with higher scores indicati greater distress. A cardiovascular reactivity risk (CRR) score was derived from laboratory mental stress testing by assigning quartile-based points for three maladaptive responses, previously shown to be associated with adverse outcomes: lower rate-pressure product reactivity, greater stress-related decline in flow-mediated dilation, and lower peripheral arterial tonometry ratio, a measure of digital vasoconstriction. CRR scores ranged from 0 to 9, with higher scores indicating more maladaptive reactivity. Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular death, nonfatal myocardial infarction, or heart failure hospitalization. Fine-Gray models tested associations with MACE after adjustment for demographic and clinical risk factors. Mean age of the cohort was 58.7 ± 10.1 years; 32.4% were women and 40.3% were Black. The PDS and CRR scores were weakly correlated. Over a median of 5.9 years, 121 MACE occurred. In mutually adjusted models, each 1-SD higher PDS was associated with a 20% higher risk of MACE (sHR, 1.20; 95% CI, 1.11-1.30), and each 1-SD higher CRR with a 44% higher risk (sHR, 1.44; 95% CI, 1.33-1.56; both p < 0.01). There was no statistically significant evidence of nonlinearity for PDS or CRR. Addition of CRR to the base model increased the 5-year AUC from 0.77 to 0.79 (ΔAUC = 0.03; p = 0.03), whereas PDS alone did not materially improve discrimination. In complementary median-defined analyses, participants with high PDS and high CRR had the highest observed risk compared with those with low PDS and low CRR (sHR, 2.44; 95% CI, 1.93-3.09), without significant multiplicative interaction. In stable CAD, psychological distress and maladaptive cardiovascular reactivity were independent determinants of incident MACE, indicating that both the burden of psychological distress during life and the pathophysiologic reactivity to stress are indicators of psychological stress-mediated residual risk in CAD.
中文摘要:心理应激和心血管对心理应激的反应异常均与冠心病不良预后相关,但其独立及联合的预后意义尚不明确。本研究纳入了来自两个前瞻性队列的648名稳定性冠心病参与者。通过问卷评估抑郁症状、焦虑、愤怒、感知压力及创伤后应激症状,构建了基于排名的心理困扰评分(PDS),分数越高表示困扰越重。心血管反应风险(CRR)评分源自实验室心理应激测试,根据三种已证实与不良结局相关的适应不良反应分配四分位数点数:较低的压积反应、较大的流介导扩张力应激相关下降以及较低的周围动脉张力测量比率(反映数字血管收缩)。CRR评分范围为0至9分,分数越高表示适应不良反应越严重。主要不良心血管事件(MACE)定义为心血管死亡、非致死性心肌梗死或心力衰竭住院的复合终点。采用Fine-Gray模型在调整人口统计学和临床危险因素后测试与MACE的关联。队列平均年龄为58.7±10.1岁,女性占32.4%,黑人占40.3%。PDS与CRR评分呈弱相关。中位随访5.9年间发生121例MACE。在相互调整的模型中,PDS每增加1个标准差,MACE风险增加20%(sHR, 1.20; 95% CI, 1.11-1.30),CRR每增加1个标准差,风险增加44%(sHR, 1.44; 95% CI, 1.33-1.56;均p<0.01)。未发现PDS或CRR存在显著的非线性证据。将CRR加入基础模型使5年AUC从0.77提高至0.79(ΔAUC=0.03; p=0.03),而单独加入PDS未实质性改善区分度。在互补的中位数定义分析中,与低PDS和低CRR组相比,高PDS和高CRR组的观察风险最高(sHR, 2.44; 95% CI, 1.93-3.09),且无显著的乘法交互作用。在稳定性冠心病中,心理困扰和适应不良的心血管反应是MACE发生的独立决定因素,表明生活中的心理困扰负担及对应激的病理生理反应均是冠心病中心理应激介导残余风险的指标。
14心血管病筛查 (1篇)
基础研究 (1篇)
The electrocardiogram (ECG) is an established tool in cardiovascular prevention, identifying silent arrhythmias, hypertrophy, prior myocardial infarction, conduction disease, and inherited electrical disorders. However, conventional interpretation captures only a fraction of the information embedded in the cardiac electrical signal. Because the ECG is inexpensive, non-invasive, standardized, and already acquired at scale, it provides an attractive substrate for artificial intelligence (AI)-enabled screening and risk stratification. Deep-learning models can identify latent signatures of ventricular dysfunction, structural heart disease, atrial fibrillation, cardiomyopathy, heart failure, and mortality risk. Importantly, evidence is beginning to extend beyond retrospective validation: prospective implementation studies have increased disease detection, while randomized data suggest that AI-ECG-guided clinical alerts may improve outcomes in selected high-risk populations. Whether such benefits extend to preventive populations remains uncertain. This review examines the preventive role of conventional, ambulatory, and wearable ECGs and distinguishes AI applications for detection, prediction, prognostication, treatment selection, and longitudinal monitoring. We argue that performance metrics alone are insufficient. Preventive value requires a defined target population, calibrated and externally validated predictions, an appropriate confirmatory test, a feasible clinical workflow, and an intervention proven to improve outcomes. The most credible near-term applications are those that triage patients to established diagnostic pathways, such as echocardiography or prolonged rhythm monitoring. The central challenge is therefore to transform accurate AI-ECG predictions into actionable, affordable, scalable, safe, and equitable prevention.
中文摘要:心电图是心血管预防的既定工具,可识别隐匿性心律失常、肥厚、既往心肌梗死、传导疾病及遗传性电生理紊乱。然而,传统解读仅能捕捉心脏电信号中嵌入信息的一小部分。由于心电图具有低成本、无创、标准化且已大规模采集的特点,它成为人工智能筛查和风险分层的理想基础。深度学习模型可识别心室功能障碍、结构性心脏病、心房颤动、心肌病、心力衰竭及死亡风险的潜在特征。目前证据已开始超越回顾性验证:前瞻性实施研究提高了疾病检出率,随机数据表明人工智能心电图引导的临床警报可能改善特定高危人群的预后。此类益处是否延伸至预防性人群仍不确定。本综述考察了常规、动态及可穿戴心电图的预防作用,并区分了用于检测、预测、预后、治疗选择及纵向监测的人工智能应用。我们认为仅凭性能指标不足够。预防价值需具备明确的目标人群、校准且经外部验证的预测结果、合适的确认测试、可行的临床工作流程以及被证实能改善预后的干预措施。最可信的近端应用是将患者分流至既定诊断路径,如超声心动图或延长节律监测。核心挑战在于将准确的人工智能心电图预测转化为可操作、负担得起、可扩展、安全且公平的预防手段。
15心血管代谢病 (1篇)
临床研究 (1篇)
The association of long working hours with cardiometabolic disease accumulation remains unclear. Cardiometabolic multimorbidity (CMM) was defined as the coexistence of at least two of the following conditions: type 2 diabetes, ischaemic heart disease and stroke. We studied 269,197 employed UK Biobank participants free of cardiometabolic disease (CMD) at baseline. Weekly working hours were analysed in five categories, with 35-40 h/week as reference. Cox models assessed incident first CMD (FCMD), CMM and all-cause mortality. Multistate models assessed progression from no CMD to FCMD and from FCMD to CMM, with death possible from each state. Models were adjusted for demographic, socioeconomic, occupational and family-history factors. Estimates were pooled across 50 multiply imputed datasets. Within the disease observation window, 25,190 participants developed FCMD and 2,824 developed CMM. Working ≥55 h/week was associated with FCMD (hazard ratio [HR] 1.117, 95% confidence interval [CI] 1.057-1.180). Incident CMM from baseline was associated with 41-48 h/week (1.128, 1.010-1.260) and 49-54 h/week (1.205, 1.042-1.393); the estimate for ≥55 h/week was 1.144 (0.973-1.346). For FCMD-to-CMM progression, the corresponding HR were 1.141 (1.021-1.274), 1.129 (0.976-1.306) and 1.093 (0.929-1.286). Spline analyses supported overall associations with FCMD and incident CMM from baseline (both P<0.001), but not a clear association with FCMD-to-CMM progression (P=0.083). Long working hours were associated with first CMD onset and incident CMM in some working-hour groups; FCMD-to-CMM progression showed no clear increasing gradient. These findings support considering working time in cardiometabolic risk assessment while distinguishing initial disease development from subsequent progression.
中文摘要:长工作时间与心血管代谢疾病累积之间的关联尚不明确。本研究将心血管代谢多病共存定义为至少同时存在以下三种情况中的两种:2型糖尿病、缺血性心脏病和中风。我们分析了英国生物银行中269,197名基线时无心血管代谢疾病的就业参与者。每周工作时间分为五类,以35至40小时/周作为参照组。Cox模型评估了首次发生的心血管代谢疾病、多病共存及全因死亡率的多重状态模型评估了从无心血管疾病到首次发病以及从首次发病到多病共存的进展过程,并考虑了各状态下可能的死亡情况。模型调整了人口学、社会经济、职业和家庭史因素。估计值在50个多重插补数据集中进行汇总。在疾病观察窗口内,25,190名参与者发展为首次心血管疾病,2,824名参与者发展为多病共存。每周工作55小时及以上与首次心血管疾病的发生相关(风险比1.117,95%置信区间1.057至1.180)。基线时发生的多病共存与工作41至48小时/周(1.128,1.010至1.260)和49至54小时/周(1.205,1.042至1.393)相关;工作55小时及以上的估计值为1.144(0.973至1.346)。从首次发病到多病共存的进展过程中,相应的风险比分别为1.141(1.021至1.274)、1.129(0.976至1.306)和1.093(0.929至1.286)。样条分析支持首次心血管疾病发生和基线时发生的多病共存的整体关联,但未显示从首次发病到多病共存进展的明确关联。长工作时间与某些工作时长组别的首次心血管疾病发生和发生的多病共存相关;首次发病到多病共存的进展未显示出明确的递增梯度。这些发现支持在心血管代谢风险评估中考虑工作时间,同时区分初始疾病发展与后续进展。
16心肌梗死/ACS (1篇)
临床研究 (1篇)
Air pollutants and ambient temperature are important cardiovascular disease determinants, and communicating their overall risk is important for cardiovascular patient management. We developed a composite Air Health Index (AHI) by linking high-resolution exposure data with 1,207,625 acute myocardial infarction (AMI) cases across 325 Chinese cities. The AHI for AMI aggregates excess morbidity risks from fine particulate matter, nitrogen dioxide, ozone, and ambient temperature into a normalized scale (0-10+). Compared with existing metrics, the AHI for AMI showed better predictive performance for AMI onset than the Air Quality Index (AQI) and Air Quality Health Index (AQHI). Each interquartile range increase in the AHI for AMI was associated with a 5.97% (95% confidence interval [CI]: 5.32%-6.63%) increase in AMI incidence, surpassing the AQHI (3.33%, 95% CI: 2.93%-3.72%) and AQI (2.04%, 95% CI: 1.73%-2.35%). The AHI for AMI showed a nearly linear exposure-response relationship with no evident threshold and accounted for 8,534 per 100,000 AMI cases nationally. These associations were consistently validated in an independent external data set, supporting the robustness and generalizability of the index. In conclusion, the AHI for AMI provides an integrative and practical framework for assessing environmental health risks, offering actionable guidance for cardiovascular patient management.
中文摘要:空气污染物和气温是重要的心血管疾病决定因素,对其整体风险进行沟通对于心血管患者管理至关重要。我们通过将高分辨率暴露数据与覆盖中国325个城市的1,207,625例急性心肌梗死(AMI)病例相链接,开发了一种复合空气健康指数(AHI)。该AMI的AHI将细颗粒物、二氧化氮、臭氧和气温引起的超额发病率风险整合到一个标准化量表(0-10+)中。与现有指标相比,AMI的AHI在预测AMI发病方面表现出优于空气质量指数(AQI)和空气质量健康指数(AQHI)的性能。AMI的AHI每增加一个四分位距,AMI发病率增加5.97%(95%置信区间[CI]:5.32%-6.63%),超过了AQHI(3.33%,95% CI:2.93%-3.72%)和AQI(2.04%,95% CI:1.73%-2.35%)。AMI的AHI显示出近乎线性的暴露反应关系,无明显阈值,在全国范围内占每10万人中8,534例AMI病例。这些关联在独立的外部数据集中得到了一致验证,支持了该指数的稳健性和普遍性。总之,AMI的AHI为评估环境健康风险提供了一个综合且实用的框架,为心血管患者管理提供了可操作的指导。
17肥厚型心肌病 (1篇)
临床研究 (1篇)
Hypertrophic cardiomyopathy (HCM) is a prevalent heterogenous genetic cardiac disorder. In the cardiac myosin inhibitor era, the guideline-directed management of HCM remains an emerging frontier worldwide. Septal myectomy has been the gold standard treatment option for obstructive HCM over the past 60 years. However, the complexity of this procedure and required expertise (and lack of qualified training) have limited its success and availability beyond high-volume HCM centers. Transapical beating-heart septal myectomy (TA-BSM), a newly developed innovative technique, simplifies conventional septal myectomy by eliminating the need for sternotomy, cardiopulmonary bypass, and aortotomy. Most important, the inclusion of real-time intraoperative echocardiographic guidance and evaluation makes TA-BSM safer, more precise, cost-effective, and reproducible. The apparent advantages of TA-BSM, including substantial reductions in surgical trauma and operating times and much faster postoperative recovery in patients with obstructive HCM, are encouraging. TA-BSM is particularly feasible in patients with long-segment obstruction, or small aortic valve annulus, or in those who had undergone previous cardiac operations. The frequent resolution of systolic anterior motion and associated mitral regurgitation after TA-BSM, without concomitant mitral valve intervention, highlights the central role of intraoperative echocardiography and close surgeon-echocardiographer collaboration in achieving optimal procedural outcomes. Further multicenter evaluation of TA-BSM will help define its role among septal reduction strategies for patients with obstructive HCM.
中文摘要:肥厚型心肌病HCM是一种普遍存在的异质性遗传性心脏疾病。在心脏肌球蛋白抑制剂时代,指南指导的HCM管理仍是全球范围内的新兴前沿领域。在过去60年中,室间隔切除术一直是梗阻性HCM的标准治疗方案。然而,该手术的复杂性及所需的专业技能(以及合格培训的缺乏)限制了其在高容量HCM中心之外的成功率和可及性。经心尖跳动心脏室间隔切除术TA-BSM是一种新开发的创新技术,通过消除胸骨切开术、体外循环和主动脉切口的需求,简化了传统的室间隔切除术。最重要的是,实时术中超声心动图引导和评估的加入使TA-BSM更安全、更精确、更具成本效益且可重复。梗阻性HCM患者术后恢复明显加快、手术创伤和手术时间大幅减少等显著优势令人鼓舞。TA-BSM在长段梗阻或主动脉瓣环较小的患者中,以及既往接受过心脏手术的患者中尤其可行。TA-BSM后收缩期二尖瓣前向运动SAM及其相关的二尖瓣反流频繁得到解决,无需同时进行二尖瓣干预,这突显了术中超声心动图和外科医生与超声医师紧密合作在实现最佳手术结果中的核心作用。对TA-BSM的进一步多中心评估将有助于明确其在梗阻性HCM患者室间隔减容策略中的地位。
18心脏外科/CABG (1篇)
临床研究 (1篇)
Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0-73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94-2.31]; P=0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P=0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively (P=0.099). In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02338947.
中文摘要:衰弱与冠状动脉旁路移植术(CABG)后的不良预后相关。然而,预衰弱的衰弱患者中非体外循环CABG(OPCAB)与体外循环CABG(ONCAB)的比较疗效仍不确定。这项多中心随机开放标签试验于2018年1月至2024年12月期间招募了年龄≥60岁且被分类为预衰弱或衰弱的患者,按1:1比例随机分组。主要终点为30天内死亡、心肌梗死、卒中、肾衰竭、急性呼吸窘迫综合征或因出血再次手术的复合结局。次要终点包括通气时间、重症监护室和住院时间、输血需求、血运重建的完整性、30天手术伤口感染以及术前和1年后的神经认知功能。分析遵循意向性治疗原则;估算相对风险及95%置信区间。共纳入508名患者(OPCAB组n=258;ONCAB组n=250;中位年龄68岁[四分位距65.0-73];女性占30.5%)。接受OPCAB的28名患者(10.9%)和接受ONCAB的40名患者(16.0%)出现了主要复合结局(相对风险1.47[95%CI 0.94-2.31];P=0.09)。ONCAB组的手术伤口感染发生率更高(20例[8.0%]对比9例[3.5%];P=0.04)。在1年时未观察到神经认知或生活质量方面的显著差异。OPCAB组和ONCAB组的估计1年生存概率分别为96.1%和92.8%(P=0.099)。在接受CABG的预衰弱和衰弱患者中,OPCAB和ONCAB的主要复合结局发生率相似。在神经认知结局方面未观察到OPCAB与ONCAB之间的显著差异。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT02338947。
19外周血管病 (1篇)
临床研究 (1篇)
People with peripheral artery disease (PAD) are often misdiagnosed or diagnosed late and, even after diagnosis, are undertreated with both pharmacologic and invasive therapies. The disease is associated with an increased risk of mortality, myocardial infarction, stroke, other vascular disease, limb loss, and reduced quality of life. Although the risks and long-term management of PAD are well documented, these risks are acutely magnified when PAD exists as a comorbidity in patients hospitalized for other cardiovascular or medical conditions. Procedures requiring vascular access for the treatment of acute myocardial infarction, cardiogenic shock, or valvular heart disease, as well as procedures for the treatment of the patient's underlying PAD, require special consideration in patients with PAD. Familiarity with the use and placement of mechanical circulatory support in patients with PAD, as well as the management of recent endovascular or surgical vascular interventions, is essential for providing appropriate care in the acute care setting.
中文摘要:外周动脉疾病(PAD)患者常被误诊或诊断延迟,且即使确诊后,在药物和介入治疗方面也存在治疗不足的问题。该疾病与死亡率增加、心肌梗死、卒中、其他血管疾病、肢体丧失及生活质量下降的风险升高相关。尽管PAD的风险和长期管理已有充分记录,但当PAD作为合并症存在于因其他心血管或内科疾病住院的患者中时,这些风险会急剧放大。为治疗急性心肌梗死、心源性休克或瓣膜性心脏病而进行的需要血管通路的程序,以及针对患者潜在PAD的治疗程序,在PAD患者中需特别考量。熟悉机械循环支持在PAD患者中的使用与置入,以及近期血管内或外科血管干预的管理,对于在急性医疗环境中提供适当护理至关重要。
20心脏纤维化 (1篇)
基础研究 (1篇)
Dynamic interactions between micronuclear and mitochondrial reactive oxygen species influence micronuclear homeostasis and associated heart diseases. However, the molecular mechanisms underlying micronuclear rupture during cardiac fibrosis remain largely unknown. Cardiac fibroblast-specific YTHDF1-deficient and wild-type mice were treated with isoproterenol/transverse aortic constriction to induce cardiac fibrosis. To investigate the roles of YTHDF1, p66shc, and m6A modification in cardiac fibrosis, AAV9 vectors carrying a cardiac fibroblast-specific periostin promoter were used to induce p66shc overexpression or deliver small hairpin RNA targeting YTHDF1, along with the m6A inhibitor 3-deoxyadenosine. Histological and molecular biology analyses were conducted to examine how YTHDF1 regulates p66shc mRNA stability during cardiac fibrosis. Additionally, p66shc reconstitution in YTHDF1-deficient cardiac fibroblasts and mouse hearts was performed to assess its effects on micronuclear rupture and fibrosis. Human atrial fibrillation heart tissue was used to validate these findings.During cardiac fibrosis, the increased micronuclear rupture was accompanied by p66shc upregulation and excessive mitochondrial reactive oxygen species production. Fibroblast-specific p66shc depletion inhibited micronuclear rupture, mitochondrial reactive oxygen species, and fibroblast pyroptosis, and alleviated cardiac fibrosis. Notably, p66shc upregulation was correlated with elevated m6A modification of mRNA. Mechanistically, YTHDF1 recognized the m6A-modified site on p66shc mRNA, enhancing its stability and translation. Conversely, YTHDF1 knockdown inhibits the stability and expression of p66shc, leading to opposing effects. In human atrial fibrillation heart tissues, increased YTHDF1 and p66shc levels were associated with enhanced micronuclear rupture, excessive mitochondrial reactive oxygen species production, fibroblast pyroptosis, and cardiac fibrosis. This study revealed a novel epigenetic mechanism in which m6A methylation of p66shc drives micronuclear rupture and exacerbates cardiac fibrosis. These findings provide new insights into potential measures for preventing cardiac fibrosis. These findings reveal a clinically significant role of the YTHDF1/p66shc axis in mitigating cardiac fibrosis. Targeting m6A methylation of p66shc to suppress mitochondrial ROS generation, micronucleus rupture, and cardiac fibroblast pyroptosis may offer a promising therapeutic strategy for cardiac fibrosis.
中文摘要:微核与线粒体活性氧的动态相互作用影响微核稳态及相关心脏病。然而,心脏纤维化过程中微核破裂的分子机制尚不清楚。本研究使用异丙肾上腺素/横主动脉缩窄诱导小鼠心脏纤维化,并构建了成纤维细胞特异性YTHDF1缺陷及野生型小鼠模型。为探究YTHDF1、p66shc及m6A修饰在心脏纤维化中的作用,采用携带成纤维细胞特异性periostin启动子的AAV9载体诱导p66shc过表达或递送靶向YTHDF1的小发夹RNA,并联合使用m6A抑制剂3-脱氧腺苷。通过组织学和分子生物学分析考察YTHDF1如何调节心脏纤维化过程中p66shc mRNA的稳定性。此外,在YTHDF1缺陷的成纤维细胞和小鼠心脏中进行p66shc重建以评估其对微核破裂和纤维化的影响,并利用人类心房颤动心脏组织验证这些发现。在心脏纤维化过程中,微核破裂增加伴随p66shc上调及线粒体活性氧过度产生。成纤维细胞特异性耗竭p66shc可抑制微核破裂、线粒体活性氧及成纤维细胞焦亡,并减轻心脏纤维化。值得注意的是,p66shc上调与mRNA的m6A修饰水平升高相关。机制上,YTHDF1识别p66shc mRNA上的m6A修饰位点,增强其稳定性和翻译。相反,YTHDF1敲低抑制p66shc的稳定性和表达,产生相反效果。在人心房颤动心脏组织中,YTHDF1和p66shc水平升高与微核破裂增加、线粒体活性氧过度产生、成纤维细胞焦亡及心脏纤维化相关。本研究揭示了一种新的表观遗传机制,即p66shc的m6A甲基化驱动微核破裂并加剧心脏纤维化。这些发现为预防心脏纤维化的潜在措施提供了新见解,揭示了YTHDF1/p66shc轴在减轻心脏纤维化中的临床意义。靶向p66shc的m6A甲基化以抑制线粒体ROS生成、微核破裂和心脏成纤维细胞焦亡可能为心脏纤维化提供有前景的治疗策略。
21基础/转化 (1篇)
基础研究 (1篇)
Alcohol-related cardiovascular risk is being fundamentally reappraised. Observational associations suggesting cardioprotection with light-to-moderate drinking have been challenged by contemporary cohort analyses, Mendelian-randomization studies, biomarker-informed investigations, and updated public-health guidance. Uncertainty nevertheless persists at very low exposure levels and for selected coronary or all-cause outcomes. Alcohol is therefore best viewed as a dose-, pattern-, and host-dependent cardiovascular stressor. Acute or binge drinking, sustained heavy intake, chronic intake with episodic binges, and withdrawal produce overlapping but distinct phenotypes, including hypertension, atrial fibrillation, ventricular arrhythmias, sudden death, alcohol-associated cardiomyopathy, heart failure, stroke, and vascular disease. A systems-cardiology framework is presented in which direct myocardial injury, electrical instability, haemodynamic and autonomic stress, vascular and microvascular dysfunction, and disrupted inter-organ signalling interact. Ethanol and acetaldehyde toxicity, redox imbalance, microbial and inflammatory mediators, neurohumoral activation, and metabolic or electrolyte disturbances can impair endothelial signalling, mitochondrial energetics, excitation-contraction coupling, electrical stability, and repair. Pathway dominance varies across exposure patterns and susceptible hosts; coronary microvascular dysfunction may represent a convergence pathway rather than an obligatory mediator. Cumulative injury can diminish perfusion, contractile, electrical, autonomic, and exercise reserve. Alcohol-related cardiovascular ageing is proposed as a unifying cumulative phenotype encompassing mitochondrial dysfunction, oxidative and nitrative stress, inflammageing, senescence, impaired repair, circadian and epigenetic dysregulation, fibrosis, and ventriculo-arterial uncoupling, although direct human evidence remains incomplete. Age, biological sex, genetics, comorbidities, sleep-circadian disruption, nutrition, medications, and polysubstance misuse may modify pathway dominance and reversibility. Structured exposure assessment and alcohol reduction or abstinence, when indicated, are actionable components of cardiovascular prevention and care.
中文摘要:与酒精相关的心血管风险正在被根本性地重新评估。提示轻度至中度饮酒具有心脏保护作用的观察性关联,已受到当代队列分析、孟德尔随机化研究、生物标志物导向调查以及更新后的公共卫生指南的挑战。然而,在极低暴露水平及特定冠状动脉或全因结局方面仍存在不确定性。因此,酒精最好被视为一种剂量、模式和宿主依赖的心血管应激源。急性或暴饮、持续大量摄入、慢性摄入伴间歇性暴饮以及戒断会产生重叠但独特的表型,包括高血压、心房颤动、室性心律失常、猝死、酒精相关性心肌病、心力衰竭、中风和血管疾病。本文提出了一种系统心脏病学框架,其中直接心肌损伤、电不稳定、血流动力学和自主神经应激、血管及微血管功能障碍以及器官间信号传导紊乱相互作用。乙醇和乙醛毒性、氧化还原失衡、微生物和炎症介质、神经体液激活以及代谢或电解质紊乱可损害内皮信号传导、线粒体能量代谢、兴奋收缩耦合、电稳定性和修复能力。通路优势随暴露模式和易感宿主而异;冠状动脉微血管功能障碍可能代表一种汇聚通路而非强制性介导因素。累积性损伤可降低灌注、收缩、电生理、自主神经及运动储备。酒精相关的心血管衰老被提出作为一种统一的累积表型,涵盖线粒体功能障碍、氧化和硝化应激、炎症衰老、衰老、修复受损、昼夜节律和表观遗传失调、纤维化以及心室动脉解耦联,尽管直接的人类证据仍不完整。年龄、生物学性别、遗传因素、合并症、睡眠昼夜节律紊乱、营养、药物和多物质滥用可能改变通路优势和可逆性。结构化的暴露评估以及在指征明确时减少或戒除酒精摄入,是心血管预防和护理中可操作的组成部分。
22心肌病 (1篇)
基础研究 (1篇)
Routine genetic testing of patients with cardiomyopathy has identified many causative genetic variants. However, in most instances, the impact of these variants on physiological function and clinical outcomes remains unclear. Here we develop a high-throughput human induced pluripotent stem-cell-based platform to measure the effects of variants in cardiac troponin I (encoded by TNNI3) on systolic and diastolic force generation and calcium handling. By integrating contractility and calcium signaling, we accurately distinguish pathogenic from nonpathogenic TNNI3 variants and characterize the pathogenic effects of variants of uncertain significance. Further, by evaluating the clinical presentations of patients with TNNI3 cardiomyopathy from a single site, we demonstrate that diastolic function in vitro correlates with age at onset (R2 = 0.6), a measure of disease severity. The ability to comprehensively characterize in vitro variant effects that correlate with clinical outcomes should help identify mechanisms underlying variable disease severity and enhance the discovery of class-targeted treatments.
中文摘要:对心肌病患者进行常规基因检测已发现许多致病性遗传变异。然而,在大多数情况下,这些变异对生理功能和临床结果的影响仍不清楚。在此,我们开发了一种基于人多能干细胞的高通量平台,用于测量肌钙蛋白I(由TNNI3编码)的变异对收缩期和舒张期力量生成及钙处理的影响。通过整合收缩力和钙信号传导,我们能够准确区分致病性和非致病性TNNI3变异,并表征意义未明变异的致病效应。此外,通过评估来自单一中心的TNNI3心肌病患者的临床表现,我们证明体外舒张功能与发病年龄(R2=0.6)相关,后者是疾病严重程度的衡量指标。全面表征与临床结果相关的体外变异效应的能力,应有助于识别可变疾病严重程度的潜在机制,并增强靶向治疗的发现。
23其他 (1篇)
临床研究 (1篇)
The primary goal of randomized controlled trials is typically to understand the impact of a treatment on an outcome(s) of interest. Randomization is a critical design component for making these types of cause-and-effect inferences, as it ensures balance between the treatment groups in terms of both known and unknown confounders (factors related to both exposure and outcome), which can introduce bias when imbalanced across exposure (treatment) groups. When comparing treatment groups in the primary analysis of a randomized controlled trial, participants are typically included with the group to which they were randomized, following a framework referred to as intention to treat (ITT). ITT intentionally does not account for postrandomization events (eg, protocol nonadherence) in order to maintain the integrity of the randomization. There are other non-ITT frameworks for randomized controlled trial analyses, including the common per-protocol, as-treated, and modified ITT analyses. This article summarizes ITT and non-ITT frameworks and the research questions which they address, discusses their trade-offs, and provides information about operationalizing randomized controlled trial analyses, including discussion of the available topical guidance, considerations for conducting analyses in the face of missing data, and evolving statistical methods for non-ITT analyses.
中文摘要:随机对照试验的主要目标通常是了解治疗对特定结局的影响。随机化是进行因果推断的关键设计要素,因为它能确保治疗组在已知和未知的混杂因素(与暴露和结局均相关的因素)之间保持平衡,这些因素若在各治疗组间分布不均会引入偏倚。在进行随机对照试验的主要分析时,参与者通常按照其被随机分配的组别纳入分析,这种框架被称为意向性治疗(ITT)。ITT有意不纳入随机化后的事件(如方案依从性差),以维持随机化的完整性。随机对照试验的分析还存在其他非ITT框架,包括常见的符合方案集、按治疗方案和修改后的意向性治疗分析。本文总结了ITT和非ITT框架及其所解决的研究问题,讨论了它们的权衡利弊,并提供了关于实施随机对照试验分析的信息,包括对现有相关指南的讨论、处理缺失数据时的考量以及用于非ITT分析的统计方法的演变。